
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39237601
71202
10.1038/s41598-024-71202-y
Article
Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
Mochel Jonathan P. jpmochel@uga.edu

12
Ward Jessica L. 3
Blondel Thomas 4
Kundu Debosmita 2
Merodio Maria M. 3
Zemirline Claudine 4
Guillot Emilie 4
Giebelhaus Ryland T. 5
de la Mata Paulina 5
Iennarella-Servantez Chelsea A. 2
Blong April 3
Nam Seo Lin 5
Harynuk James J. 5
Suchodolski Jan 6
Tvarijonaviciute Asta 7
Cerón José Joaquín 7
Bourgois-Mochel Agnes 12
Zannad Faiez 8
Sattar Naveed 9
Allenspach Karin 12
1 https://ror.org/00te3t702 grid.213876.9 0000 0004 1936 738X Precision One Health Initiative, Department of Pathology, University of Georgia College of Veterinary Medicine, 501 D.W. Brooks Drive, Athens, GA 30602 USA
2 https://ror.org/04rswrd78 grid.34421.30 0000 0004 1936 7312 SMART Pharmacology, Iowa State University, Ames, IA 50011-1250 USA
3 https://ror.org/04rswrd78 grid.34421.30 0000 0004 1936 7312 Veterinary Clinical Sciences, Iowa State University, Ames, IA 50011-1250 USA
4 Ceva Santé Animale, 33500 Libourne, France
5 grid.17089.37 0000 0001 2190 316X The Metabolomics Innovation Centre, Department of Chemistry, University of Alberta, T6G 2G2 Edmonton, Canada
6 https://ror.org/01f5ytq51 grid.264756.4 0000 0004 4687 2082 Gastrointestinal Laboratory, Texas A&M University, College Station, TX 77845 USA
7 https://ror.org/03p3aeb86 grid.10586.3a 0000 0001 2287 8496 Interdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), Veterinary School, Regional Campus of International Excellence ‘Campus Mare Nostrum’, University of Murcia, Campus de Espinardo s/n, Espinardo, 30100 Murcia, Spain
8 https://ror.org/04vfs2w97 grid.29172.3f 0000 0001 2194 6418 Université de Lorraine, Centre d’Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT, 54000 Nancy, France
9 https://ror.org/00vtgdb53 grid.8756.c 0000 0001 2193 314X School of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA Scotland, UK
5 9 2024
5 9 2024
2024
14 206658 4 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cardiovascular-kidney-metabolic health reflects the interactions between metabolic risk factors, chronic kidney disease, and the cardiovascular system. A growing body of literature suggests that metabolic syndrome (MetS) in individuals of normal weight is associated with a high prevalence of cardiovascular diseases and an increased mortality. The aim of this study was to establish a non-invasive preclinical model of MetS in support of future research focusing on the effects of novel antidiabetic therapies beyond glucose reduction, independent of obesity. Eighteen healthy adult Beagle dogs were fed an isocaloric Western diet (WD) for ten weeks. Biospecimens were collected at baseline (BAS1) and after ten weeks of WD feeding (BAS2) for measurement of blood pressure (BP), serum chemistry, lipoprotein profiling, blood glucose, glucagon, insulin secretion, NT-proBNP, angiotensins, oxidative stress biomarkers, serum, urine, and fecal metabolomics. Differences between BAS1 and BAS2 were analyzed using non-parametric Wilcoxon signed-rank testing. The isocaloric WD model induced significant variations in several markers of MetS, including elevated BP, increased glucose concentrations, and reduced HDL-cholesterol. It also caused an increase in circulating NT-proBNP levels, a decrease in serum bicarbonate, and significant changes in general metabolism, lipids, and biogenic amines. Short-term, isocaloric feeding with a WD in dogs replicated key biological features of MetS while also causing low-grade metabolic acidosis and elevating natriuretic peptides. These findings support the use of the WD canine model for studying the metabolic effects of new antidiabetic therapies independent of obesity.

Keywords

Western diet
Metabolic syndrome
Cardiorenal metabolic diseases
One health
Subject terms

Cardiovascular diseases
Metabolic diseases
CEVA Sante AnimalePO1126151 PO1126151 PO1126151 issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from insulin resistance and impaired insulin secretion1. Recent data from the National Diabetes Statistics Report indicate that 37.3 million Americans suffer from T2DM2. In addition, the economic cost of diabetes and prediabetes was estimated to reach $322 billion in the U.S in 2012. Accumulating data from several large, placebo-controlled studies suggests that sodium-glucose transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists offer therapeutic benefits in the management of cardiovascular diseases, regardless of the patient's diabetic status3–11. In addition to their effects on glucose excretion, SGLT-2-inhibitors positively impact systemic metabolism by reducing inflammation and oxidative stress, shifting metabolism towards ketone body production, promoting autophagy, and suppressing glycation end-product signaling9. These findings align with the American Heart Association's recent definition of cardiovascular-kidney-metabolic health12, a concept which represents the interplay between metabolic disorders like T2DM, chronic kidney disease, and the cardiovascular system (Fig. 1).Fig. 1 Molecular bases for the interrelationship between cardiovascular, renal, and metabolic diseases. Adjusted and simplified from Kadowaki et al. 120.

The pleiotropic effects of SGLT-2 inhibitors and GLP-1 agonists provide an opportunity to target several cardiorenal metabolic disorders. This can be achieved experimentally using a disease model that replicates key features of metabolic syndrome (MetS), a cluster of risk factors that include obesity, dyslipidemia, hypertension, and insulin resistance. Collectively, these factors increase the risk of developing cardiorenal diseases, metabolic dysfunction-associated steatohepatitis and T2DM9,13,14. Implementing such a model would enable future mechanistic studies to explore the metabolic effects of novel antidiabetic therapy beyond glycemic control.

Rodent models, especially mice, are commonly used in translational research due to their cost-effectiveness, ethical considerations, and ease of genetic manipulation. However, despite their widespread use, murine models often fail to accurately mimic human diseases, limiting their translational value15. In a study published in the Proceedings of the National Academy of Sciences, Seok et al.16 found that mouse models poorly replicate human inflammatory responses from various causes, reporting a poor correlation (R2 between 0.0 and 0.1) between significantly altered genes in humans and their murine equivalents. Additionally, the high failure rate of drug discovery and development highlights the urgent need for more accurate animal models in preclinical research17. The FDA Modernization Act 2.0 further emphasizes this need by restricting the use of non-informative animal models, such as rodents, in experimental drug testing prior to clinical studies18. As a result, there is an increasing incentive to use more relevant animal models, such as dogs, which often better represent chronic diseases than rodents. Dogs have a larger body size, longer lifespan, and physiological similarities to humans, and they naturally develop diseases analogous to human conditions, including cardiorenal, metabolic, inflammatory, and neurodegenerative diseases15,19–24.

Despite presenting some unique features in their lipid metabolism, such as low activity of cholesteryl ester transfer protein and an abundance of high-density lipoprotein (HDL)-bound plasma cholesterol (contributing to an athero-protective profile)25,124, dogs have been extensively used for studying metabolic obesity, diabetes, dyslipidemia, and their response to therapeutic interventions26. As such, a comprehensive analysis published in the Journal of Lipid Research identified dogs as the second most translatable model (after non-human primates) for studying dyslipidemia and related pharmacological agents in humans, among 24 animal species, including rodents, rabbits and pigs27.

In return, from the perspective of developing veterinary pharmaceuticals for spontaneous diseases in animals, the data generated in dogs from this study could guide the development of multiple therapeutic applications for SGLT-2 inhibitors and GLP-1 agonists in veterinary medicine, such as diabetes, congestive heart failure, or chronic kidney disease under the One Health paradigm28–31.

Previous studies have shown that consistent overfeeding of dogs with a high-calorie Western diet (WD) can lead to MetS, regardless of the diet’s composition32,33. However, these investigations in dogs have primarily focused on the metabolic issues associated with obesity32,34–37. In both dogs and humans, obesity triggers an adipose tissue redistribution that results in an increase in visceral (vs. subcutaneous) fat. This shift in fat deposition is independently associated with the onset of MetS. A study by Romero-Corral et al.38 analyzing data from more than 6000 subjects showed that normal weight obesity, defined as the combination of normal body mass index (BMI) and high body fat content, was associated with a high prevalence of cardiometabolic dysregulation and cardiovascular risk factors. These findings were later supported by Shi et al.39 in an analysis including 12,047 adults where normal-weight adults with MetS had the highest hazard ratio for mortality (1.70 [1.16–2.51]), compared with obese patients with MetS (1.30 [1.07–1.60]) and obese patients without MetS (1.08 [0.76–1.54]). Additionally, most clinical studies demonstrating therapeutic benefits from SGLT-2 inhibitors on cardiorenal outcome measures include a majority of non-obese patients4,7,40–42. A recent study by Adamson et al., published in the European Journal of Heart Failure, has unequivocally established that the efficacy of dapagliflozin for heart failure patients with reduced ejection fraction remains consistent regardless of their BMI43. These findings collectively support the rationale for establishing a metabolic dysfunction model that is independent of obesity to study the pharmacodynamic effects of drug candidates targeting the cardiovascular-kidney-metabolic health.

In a preliminary study conducted by our consortium, dogs isocalorically fed a WD for a few weeks presented with elevated fasting bile acids, cholesterol, triglycerides, and blood pressure compared to control44. These findings suggest that short-term feeding with a WD can induce a clinical response that mimics MetS in healthy dogs. The aim of this research was to characterize the metabolic and molecular signatures associated with a high-fat, high-monosaccharide, and low-fiber isocaloric WD after ten weeks in dogs. Once established, this preclinical model can be used to assess the therapeutic benefits of novel antidiabetic therapy in the context of obesity-independent MetS and pave the way for translational studies that could benefit both human and veterinary medicine.

Methods

Animals

Experimental procedures were approved by the Institutional Animal Care and Use Committee at Iowa State University (Protocol Number: 21-164). All methods were performed in accordance with the relevant guidelines and regulations at Iowa State University. The authors complied with ARRIVE guidelines in the completion of this study. The study population consisted of 18 neutered young adult laboratory Beagles (9 males and 9 females, aged 12–15 months) weighing between 7.5 and 11.5 kg. They originated from a colony that had been previously acclimatized to handling and blood sampling procedures. Prior to inclusion, each dog was assessed for its general health and condition with a physical examination and had received appropriate vaccinations and deworming treatments. Normal cardiovascular structure and function were confirmed through an echocardiogram performed prior to acclimation to the study facility. No dog had received topical or systemic medications within the 28 days preceding inclusion. Each animal was assigned a unique 4-letter ear tattoo for identification purposes. Throughout the in-life phase, daily evaluations of the animals’ general health and behavior were conducted by the study veterinarian (Dr. Agnes Bourgois-Mochel). Body weight and body condition scores (BCS, recorded as “underweight” vs. “ideal” vs. “overweight”) were recorded weekly using the body condition system developed at the Nestle Purina Pet Care Center45. Detailed information on the canine body condition system can be found at: https://www.purinainstitute.com/centresquare/nutritional-and-clinical-assessments/canine-body-condition-system-sheet. All observations, including any adverse events and study interventions were systematically recorded in the raw data file.

Housing

The study animals were acclimatized to the facility for one week before the start of the study. Housing conditions were strictly in accordance with the requirements set by the United States Department of Agriculture. Each dog was housed in a 16-square foot kennel (dimensions: 4ʹ × 4ʹ) with an interconnecting door, allowing for the co-housing of two animals. However, individual separation was implemented during specific periods, such as feeding times, or when necessary for specific interventions or observations.

The lighting schedule was kept from 6 a.m. to 6 p.m. The ambient temperature within the housing facilities was consistently set to 70 F (21.1 °C), with continuous monitoring. Throughout the study, the recorded temperature varied minimally, with the range extending from 67 F (19.4 °C) to 72 F (22.2 °C). Relative humidity was also closely monitored, with values fluctuating between 34 and 45%. The dogs were provided with unrestricted access to tap water, delivered via individual nipple water feeders.

Experimental design

To replicate the dietary intake of an average American diet, dogs were fed a high-fat, high-monosaccharide, low-fiber WD adjusted from parameters of the National Health and Nutrition Examination Survey (NHANES 2015–2016: Males and Females over 20 years)46 for ten weeks. Dogs were fed isocalorically based on individually calculated metabolizable energy needs. Blood samples were collected at baseline (BAS1) when dogs were fed their regular diet, and then again after ten weeks of WD feeding (BAS2).

Diet composition for BAS1 measurements

Dogs were fed a daily diet of Royal Canin® Beagle Adult dry food (12% fat content), once in the morning, around 9 a.m. The portion size for each dog was individually calculated based on weight and resting energy requirements (RER) calculated by multiplying the animal’s body weight (BW) in kilograms raised to the 0.75 power by 70: RER = 70 × (BW)0.75 (Eq 0.1). Any leftover was weighed and recorded in the raw data file. Nutritional information on the Royal Canin® Beagle Adult dry food is presented in Table 1.Table 1 Nutritional information of the Royal Canin® Beagle adult diet.

Composition	
 Dehydrated poultry protein, maize, rice, wheat, animal fats, maize gluten, hydrolyzed animal proteins, vegetable fibers, vegetable protein isolate, beet pulp, minerals, fish oil, yeasts, soya oil, psyllium husks and seeds, fructo-oligo-saccharides, hydrolyzed yeast (source of manno-oligo-saccharides), borage oil, green tea and grape extracts (source of polyphenols), hydrolyzed crustaceans (source of glucosamine), marigold extract (source of lutein), hydrolyzed cartilage (source of chondroitin)

 Nutritional additives: Vitamin A: 28,000 IU, Vitamin D3: 700 IU, E1 (Iron): 42 mg, E2 (Iodine): 4.2 mg, E4 (Copper): 5 mg, E5 (Manganese): 55 mg, E6 (Zinc): 164 mg, E8 (Selenium): 0.09 mg

	
Analytical constituents	
 Protein: 27%

 Fat content: 12%

 Crude ash: 6.1%

 Crude fibers: 3.7%

 EPA and DHA fatty acids: 3 g/kg

	
Eighteen healthy adult Beagle dogs were fed a commercial diet (Royal Canin® Beagle Adult dry food) once in the morning, around 9 a.m. The portion size for each dog was calculated based on weight and resting energy requirements (RER). Information was provided on the food manufacturer’s website (https://www.royalcanin.com/my/dogs/products/retail-products/beagle-adult-2106#). This diet contains 3463 kilocalories of metabolizable energy (ME) per kilogram or 284 kilocalories of ME per cup on an as-fed basis (calculated).

Diet composition for BAS2 measurements

Western diets were formulated to model the average intake of American subjects over 20 years from the NHANES and were fed to meet the energy and National Research Council47 requirements for adult dogs. Diets were home cooked and prepared in batch (N = 18 dogs) on a weekly basis, then stored frozen. Ingredients were purchased from the same supplier and brand to ensure consistency. Food was offered once daily in the morning, around 9 a.m. In cases where the provided meal was not entirely consumed, the remaining portion was carefully weighed and documented in the raw data file. The exact composition of the WD can be found in Table 2.Table 2 Nutritional characteristics (2A) and composition (2B) of the western diet.

2A	
Parameter	Target	Actual	
Energy (kcal)	1000.0	1000.3	
Protein (g/Mcal)	40.1	40.3	
Fat (g/Mcal)	40.8	40.9	
CHO (g/Mcal)	118.3	117.9	
Fiber (g/Mcal)	8.4	8.4	
Sugar (g/Mcal)	51.4	51.4	
Saturated fat (%)	37.0	36.4	
Macronutrients			
 % calories from Protein: 16.1%			
 % calories from Fat: 36.8%			
 % calories from CHO: 47.1%			
2B	
Ingredient	g per 1000 kcal	Amount (g) for a typical 8.5 kg dog	
Proteins			
 Ground beef, 80% lean	56.0	35.1	
 Egg protein powder	9.8	6.1	
Carbohydrates			
 Wheat bread	99.0	62.1	
 White bread	70.0	43.9	
 Light corn syrup	47.0	29.5	
Fat			
 Corn oil	11.0	6.9	
 Unsalted butter	15.5	9.7	
Supplements			
 Psyllium husk	3.0	1.9	
 Iodized salt	5.0	3.1	
 Balance.it® Canine K	14.4	9	
 Welactin Canine liquid	0.5 (mL)	0.3 (mL)	
Eighteen healthy adult Beagle dogs were fed a high-fat, high-monosaccharide, low-fiber Western diet (WD) adjusted from parameters of the National Health and Nutrition Examination Survey (NHANES) for a period of ten weeks. The dogs were provided with isocaloric feedings based on their individually calculated metabolizable energy. The diets were home cooked and offered to the dogs once daily in the morning, typically around 9 a.m.

Sample collection

Blood samples were drawn using a jugular catheter whenever possible, or from the saphenous or cephalic veins with single use needles. Blood samples were collected at baseline (BAS1) when dogs were fed their regular diet, and then again after ten weeks of WD feeding (BAS2) for measurement of:o Complete blood count (CBC) (plasma, K3 EDTA, Iowa State University College of Veterinary Medicine);

o Standard chemistry panel, including alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, total protein, triglycerides, total cholesterol, blood urea nitrogen (BUN), serum creatinine, serum bicarbonates, calcium, phosphorus, chloride, sodium and potassium (serum, plain tube, Iowa State University College of Veterinary Medicine);

o Fasting blood glucose (serum, plain tube, Iowa State University College of Veterinary Medicine);

o Glucagon (serum, plain tube, Cornell University College of Veterinary Medicine. EMD Millipore’s Glucagon Radioimmunoassay (RIA) Kit GL-32 K);

o Lipid profiling: HDL and Low-Density Lipoprotein (LDL) cholesterol (serum, plain tube, Texas A&M College of Veterinary Medicine);

o Renin-angiotensin aldosterone system (RAAS) biomarkers (serum, plain tube, Attoquant Diagnostics, Vienna);

o N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (plasma, K3 EDTA, IDEXX Laboratories, Maine. Cardiopet ProBNP Test-Canine);

o Oxidative stress biomarkers (serum, plain tube, University of Murcia Facultad de Veterinaria);

o Metabolomics, including (1) General Metabolism; (2) Complex Lipids and (3) Biogenic Amines (serum, plain tube, University of California Davis Genome Center).

Serum insulin concentrations were measured on a separate day through an oral glucose tolerance test (plain tube, Michigan State University Veterinary Diagnostic Laboratory. EMD Millipore’s Insulin Radioimmunoassay (RIA) Kit HI-14K). The dogs received an oral dose of 5 g of dextrose per kg in the form of a solution containing 1 g of dextrose powder per mL of water. Blood samples were collected at 30, 60, 90, 120, and 180 min after oral administration of the glucose solution.

Voided urine and fecal samples were collected at BAS1 and BAS2 for the purpose of conducting metabolomic analyses, including (1) General Metabolism; (2) Complex Lipids and (3) Biogenic Amines (University of California Davis Genome Center).

Serum, plasma, urine, and fecal samples were divided into separate aliquots and stored at − 80 °C prior to analysis.

BP was measured at BAS1 and BAS2 by a certified cardiologist using a Doppler device, following standard procedures from the American College of Veterinary Internal Medicine (ACVIM), as outlined in consensus panel guidelines48. As Doppler-derived single measurements of blood pressure are an estimate of systolic blood pressure (SBP)125, the abbreviation SBP will be used throughout this manuscript. To avoid any potential disruptions or bias in the recordings, these measurements were consistently taken before any blood was collected during each study period. To follow the consensus panel guidelines for assessing hypertension48 and ensure accuracy, five consecutive and consistent SBP measurements were obtained from each subject. These values were then averaged to calculate an individual estimate of SBP.

Specific analytical methods

Lipoprotein profiling

Lipoprotein profiling was carried out using the continuous lipoprotein density profiling (CLPDP) method, adhering to procedures detailed in prior literature49,50. Briefly, a solution of 0.18 M NaBiEDTA (Tokyo Chemical Industry) measuring 1280 µL was combined with 10 µL of both serum and NBD C6-ceramide (Cayman Chemical Company). Subsequently, 1150 µL of the resultant blend was allocated to a polycarbonate centrifuge container (Beckman Coulter). The samples underwent centrifugation for 6 h at 4 °C and 867,747 g using an Optima MAX-LP ultracentrifuge (Beckman Coulter) equipped with a fixed-angle rotor (MLA-130; Beckman Coulter). Immediately post-centrifugation, the samples were imaged using a fluorescence imaging system comprising a digital camera (Quantifire XI; Optronics) and a constant metal halide light source (Dolan-Jenner Industries).

The images obtained were transformed into density profiles via software analysis (OriginPro7.5; OriginLab). Lipoprotein profiles were produced by plotting the average intensity of fluorescence on the y-axis, while the actual centrifuge tube coordinates (mm) served as the x-axis. A unique numbering system was established for the statistical examination. The area under the curve (AUC) of the total fluorescence trace and each segment were used to determine the total lipoprotein intensity and fractional intensities, respectively. AUCs were then calculated for LDLs and HDLs based on their density intervals. Individual AUC values were finally normalized using the total AUC and expressed as percentage, as presented by Minamoto et al.50.

RAAS fingerprinting

Determination of angiotensin and aldosterone analytes from canine serum was derived as previously published by our consortium51–54. Briefly, serum samples were analyzed to determine the equilibrium concentrations of Angiotensin I (Ang I (1–10)), Angiotensin II (Ang II (1–8)), Angiotensin III (Ang III (2–8)), Angiotensin IV (Ang IV (3–8)), Angiotensin 1–7 (Ang1–7), Angiotensin 1–5 (Ang1–5), and aldosterone using validated Liquid Chromatography-Tandem Mass Spectrometry (LC–MS/MS) assays at a commercial laboratory (Attoquant Diagnostics, Vienna, Austria)55. Following ex vivo equilibration, each sample was spiked with a stable isotope-labeled internal standard for each angiotensin peptide and a deuterated internal standard for aldosterone (aldosterone D4). The analytes were then extracted using C18-based solid-phase extraction. The extracted samples underwent mass spectrometry analysis using a reversed-analytical column, which was operated in tandem with a XEVO TQ-S triple quadrupole mass spectrometer in multiple reaction monitoring mode. Internal standards were used to ensure analyte recovery throughout the sample preparation process for each sample. The concentrations of the analytes were calculated from the chromatograms where the integrated signals exceeded a signal-to-noise ratio of 10, considering the corresponding response factors derived from appropriate calibration curves in the serum matrix. The lower limit of quantification (LLOQ) was established at 3.0 pM, 2.0 pM, 3.0 pM, 2.0 pM, 2.5 pM, 2.0 pM and 13.9 pM for Ang I (1–10)), Ang II (1–8), Ang1–7, Ang1–5, Ang III (2–8), Ang IV (3–8) and aldosterone, respectively. Markers for renin (PRA–S) and angiotensin-converting enzyme (ACE–S) based on angiotensin were obtained from Ang II (1–8) and Ang I (1–10) concentrations by calculating their sum and ratio, respectively56. Renin-independent alternative RAAS activation (ALT–S) was calculated using the formula [(Ang 1–7 + Ang 1–5) / (Ang I + Ang II + Ang 1–7 + Ang 1–5)]57.

Oxidative stress markers

The development and validation of analytical techniques for assessing oxidative stress markers adhered to protocols outlined in previous studies58. The following provides an abridged overview of the specific procedures used in evaluating antioxidant and oxidant statuses.

Antioxidant status

The Cupric Reducing Antioxidant Capacity (CUPRAC) assay, initially described by Campos et al.59, is based on the conversion of Cu2+ to Cu+ through the action of non-enzymatic antioxidants in the serum sample. Quantification of CUPRAC followed the protocol previously validated for canine serum60, with results reported in mmol/L.

The Ferric Reducing Ability of Plasma (FRAP) assay relies on the conversion of ferric-tripyridyltriazine (Fe3+-TPTZ) to its ferrous form61. Quantification of FRAP was performed as described in previous studies60,61. Results are expressed in mmol/L.

Measurements of Trolox Equivalent Antioxidant Capacity (TEAC) followed the procedures outlined by Arnao et al.62 later adapted to canine serum samples by Rubio et al.60. The assay involves the generation of ABTS radicals and their subsequent reduction by non-enzymatic antioxidants in the serum specimen62, with results presented in mmol/L.

Total thiol (µmol/L) determination was based on the reaction between sample thiols and DTNB126,63.

The evaluation of Paraoxonase type 1 (PON-1) was based on the conversion of phenylacetate to phenol, following the same methods used for canine serum by Tvarijonaviciute et al.64. Results are expressed as IU/mL.

Quantification of Glutathione Peroxidase (GPx) activity was performed using a commercial assay kit according to the manufacturer's instructions (RANDOX Glutathione Peroxidase (Ransel) Kit RS504), as described in previous studies65,66. Results are reported in IU/ml units.

Oxidant status

The Total Oxidant Status (TOS) was determined following Erel’s method67, which had previously been applied to dog serum60. Results are expressed in µmol/L.

The Peroxide-Activity (POX-Act) assay involved the detection of total peroxides through a peroxide-peroxidase reaction using tetramethylbenzidine as the chromogenic substrate68. Results are expressed in µmol/L.

The Derivatives-Reactive Oxygen Metabolites (d-ROMs) assay used an acidic medium to react with the sample in the presence of DEPPD, as per the method previously established by Alberti et al.69. Results are reported in Carratelli Units (U.CARR).

Determination of Advanced Oxidation Protein Products (AOPP) was based on oxidized albumin and di-tyrosine containing cross-linked proteins, as described in previous studies70,71. Results are expressed in µmol/L.

Serum/urine/fecal metabolomics

General metabolism

Samples were extracted using the extraction procedure by Matyash et al.72, which includes MTBE, MeOH, and H2O. The organic (upper) phase was dried down and submitted for resuspension and injection onto the LC, while the aqueous (bottom) phase was dried down and submitted for derivatization for GC. Samples were shaken at 30 °C for 1.5 h. Then, 91 μL of MSTFA + FAMEs were added to each sample, and tubes were shaken at 37 °C for 0.5 h to complete the derivatization. Samples were then vialed, capped, and injected onto the instrument. A 7890A GC coupled with a LECO time of flight mass spectrometer (TOFMS) was used for the procedure. Then, 0.5 μL of the derivatized sample was injected using a splitless method onto a RESTEK RTX-5SIL MS column with an Intergra-Guard at 275 °C with a helium flow of 1 mL/min. The GC oven was set to hold at 50 °C for 1 min, then ramped up to 20 °C/min to 330 °C and held for 5 min. The transfer line was set to 280 °C, while the EI ion source was set to 250 °C. The mass spectrometry parameters collected data from 85 to 500 m/z at an acquisition rate of 17 spectra/second. All compounds detected were tentatively identified to the Metabolomics Standards Initiative (MSI) Level 2 with a spectral library match score of 800 or higher73.

Complex lipids

Samples were extracted using the extraction procedure by Matyash et al.72, which includes MTBE, MeOH, and H2O. The organic (upper) phase was dried down and resuspended for injection onto the LC, while the aqueous (bottom) phase was dried down and submitted for derivatization for GC. The samples were then resuspended with 110 μL of a solution of 9:1 methanol:toluene and 50 ng/mL CUDA. Samples were then shaken for 20 s, sonicated for 5 min at room temperature, and centrifuged for 2 min at 16100 rcf. Thirty-three μL of samples were aliquoted into a vial with a 50 μL glass insert for positive and negative mode lipidomics. The samples were then loaded onto an Agilent 1290 Infinity LC stack. The positive mode was run on an Agilent 6546 with a scan range of m/z 120–1200 Da and an acquisition speed of 2 spectra/s. Positive mode had between 0.5 and 2 μL injected onto an Acquity Premier BEH C18 1.7 μm, 2.1 × 50 mm column. The gradient used was 0 min 15% (B), 0.75 min 30% (B), 0.98 min 48% (B), 4.00 min 82% (B), 4.13–4.50 min 99% (B), 4.58–5.50 min 15% (B) with a flow rate of 0.8 mL/min. Another aliquot was run in negative mode on an Agilent 1290 Infinity LC stack and injected onto the same column, with the same gradient, using an Agilent 6550 QTOF mass spectrometer. The acquisition rate was two spectra per second with a scan range of m/z 60–1200 Da. The mass resolution for the Agilent 6530 is 10,000 for ESI ( +) and 20,000 for ESI (-) for the Agilent 6550.

Biogenic amines

Sample extraction for biogenic amines consisted of a liquid–liquid extraction method72 with MTBE, methanol, and water, creating a biphasic partition. The polar phase was then dried down to completion and run on a Waters Premier Acquity BEH Amide column. A short 4-min liquid chromatography method was used for the separation of polar metabolites from a starting condition of 100% LCMS H2O with 10 mM ammonium formate and 0.125% formic acid to an end condition of 100% ACN:H2O 95:5 (v/v) with 10 mM ammonium formate and 0.125% formic acid. A Sciex Triple-ToF scanned from 50 to 1500 m/z with MS/MS collection from 40 to 1000, selecting the top five ions per cycle. Data processing was done with MS-Dial using an MZ-RT list for annotations, in addition to a library for MS/MS matching.

Statistics

The sample size for this experiment was established based on preliminary data from a previous study conducted by our group44. In that study, statistically significant differences in BP and total cholesterol were observed in a group of ten dogs receiving an isocaloric WD, with an alpha level of 0.05 and a statistical power of 80%. Study variables were visually inspected for normality, summarized, and displayed as median (interquartile range [IQR]). The area under the curve for insulin time-concentrations in the serum was determined by using the linear trapezoidal method from 0 to 90 min (AUCins(0–90)). Differences between BAS1 and BAS2 were analyzed using non-parametric Wilcoxon signed rank test with continuity correction. P-values < 0.05 were considered statistically significant. The R software version 4.2.2 was used for statistical analyses. (R Core Team (2022). Graphical representation of the data was produced using the ggplot2 package in R version 4.2.2. For metabolomic analyses, the peak tables were uploaded into the Matlab® (R2023b, The Mathworks Inc., Natick, MA) environment and converted to datasets with appropriate class labels. In PLS_Toolbox (Version 9.0; Eigenvector Research, Manson, WA), a Principal Component Analysis (PCA) was performed on the autoscaled data. To determine the variables responsible for differences between groups, a Cluster Resolution Feature Selection (FS-CR) was applied74,75. For each dataset, the FS-CR process of sequential backward elimination and forward selection was repeated 100 times, permuting the subsets of data, and only variables selected 85% of the time were retained to prevent overfitting75. The distance between clusters (cluster resolution) was used to determine which variables contributed to the separation between classes75. A PCA was then performed using the selected variables from the FS-CR, and the variables and their loadings were extracted. PCA score plots were generated to visualize the relationships between samples and classes, with a 95% confidence interval plotted around the mean center of the data.

Results

Physical examination and adverse events

The study veterinarian, along with approved study personnel, conducted weekly physical examinations and reported no notable changes in the dogs’ overall condition, behavior, cardiovascular system, hydration level, respiratory system, or skin appearance throughout the study.

During the transition from their regular diet (Royal Canin® Beagle Adult) in the first baseline phase (BAS1) to the Western diet (BAS2), several dogs experienced one or more episodes of softened stools. These instances were considered “on-serious” digestive adverse events by the study veterinarian and resolved on their own within a few days. No significant adverse effects were reported over the duration of the study.

Body weight

Differences in body weight between diets (− 3.6% based on median relative change from BAS1) were statistically significant but were not considered clinically meaningful by the study veterinarian (BAS1 8.9 [7.8–9.6] kg) vs. BAS2 8.7 [7.4–9.2] kg). Similarly, no notable changes in body condition scores were reported between BAS1 (N = 0, 13 and 5 for “underweight”, “ideal” and “overweight”, respectively) and BAS2 (N = 1, 11 and 6 for “underweight”, “ideal” and “overweight”, respectively).

Complete blood count and chemistry

All hematological parameters were within normal physiological limits, and there were no clinically relevant changes in CBC between BAS1 and BAS2.

No significant changes in liver-related chemical parameters, including ALT, ALP, albumin, and total protein, were observed between BAS1 and BAS2. However, dogs fed a WD for ten weeks had a decrease in serum bicarbonate (− 2.5 [− 4.0 to − 1.0] mEq/L, P < 0.001), phosphorus (− 0.8 [− 1.3 to − 0.5] mg/dL, P < 0.001), and potassium (− 0.5 [− 0.7 to − 0.3] mEq/L, P < 0.001), and an increase in chloride concentrations (+ 1.5 [0.0–3.0] mEq/L, P = 0.001). The diet also induced some borderline statistically significant changes in calcium (P = 0.049) and sodium (P = 0.041) levels at BAS2. Additionally, there was a significant decrease in BUN at BAS2 (− 4.5 [− 5.0 to − 3.0] mg/dL, P < 0.001), along with an increase in serum creatinine (+ 0.1 [0.0–0.2] mg/dL, P = 0.001). These variations, although statistically significant, remained within physiological limits. A summary of the clinical chemistry parameters at BAS1 and BAS2 is presented in Fig. 2.Fig. 2 Temporal changes in standard clinical chemistry parameters after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber western diet. No notable alterations were observed in liver-related chemical parameters, such as ALT, ALP, albumin, and total protein, when comparing BAS1 to BAS2. Dogs at BAS2 had decreased levels of serum bicarbonates, phosphorus, and potassium, but increased levels of chloride. There was also a reduction in BUN at BAS2, along with an elevation in serum creatinine levels. Box plots represent the 25th, 50th and 75th percentile of the data ± 1.5 IQR (interquartile range). •: 0.01 < P ≤ 0.05; ••: 0.001 < P ≤ 0.01; •••: P ≤ 0.001. Summary box plots produced using the ggplot2 package in R version 4.2.2.

Fasting blood glucose, serum glucagon and insulin

The biological effects of the WD on fasting blood glucose, as well as the glucose-regulating hormones glucagon and insulin, are presented in Figs. 3 and 4. Over a span of ten weeks, the WD induced a significant increase in fasting blood glucose concentrations (Fig. 3). This increase approached the upper physiological limit, demonstrating an overall increase of 15.8% relative to baseline (BAS1 88.0 [82.0–91.0] mg/dL vs. BAS2 102.5 [95.0–109.0] mg/dL, P < 0.001). The increase in fasting blood glucose was accompanied by a non-significant trend suggesting a decrease in serum glucagon levels at BAS2 (BAS1 69.3 [64.0–77.2] pg/mL vs. BAS2 61.8 [49.8–64.3] pg/mL, P = 0.055).Fig. 3 Temporal changes in fasting blood glucose and glucagon after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber western diet. The WD resulted in a significant 16.5% increase in fasting blood glucose, approaching the upper physiological limit. This was accompanied by a trend towards lower serum glucagon levels which did not reach statistical significance. Box plots represent the 25th, 50th and 75th percentile of the data ± 1.5 IQR (interquartile range). •••: P ≤ 0.001. Summary box plots produced using the ggplot2 package in R version 4.2.2.

Fig. 4 Serum insulin time-course post-glucose tolerance test. Dogs received an oral dose of 5 g of dextrose per kg in the form of a solution containing 1 g of dextrose powder per mL of water. Blood samples were collected at 30, 60, 90, 120, and 180 min after oral administration of the glucose solution. Compared to BAS1, dogs fed an isocaloric WD for ten weeks showed a trend towards a higher peak concentration of insulin, with an increase of approximately 35% in AUCins(0–90) at BAS2. Time-course data are presented as mean ± S.E. Scatter plots produced using the ggplot2 package in R version 4.2.2.

Additionally, the results of the glucose tolerance test suggest a trend towards an elevation in peak insulin concentrations in dogs fed a WD. The median AUCins(0–90) showed a 34.9% increase from 202.7 [103.1–276.8] uIU/mL x min at BAS1 to 232.7 [144.2–276.2] uIU/mL x min at BAS2 (P = 0.39). The average (arithmetic mean) for this increase at BAS2 was 58.2% (Fig. 4).

Blood pressure

Overall, SBP measurements were significantly higher at BAS2 compared with pre-WD readings (BAS1 133.5 [126.0–141.0] mmHg vs. BAS2 143.0 [133.0–152.0] mmHg, P = 0.017) (Fig. 5A).Fig. 5 Temporal changes in systolic blood pressure (A) and NT-proBNP (B) after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber western diet. (A) Dogs fed a WD for ten weeks had significantly higher blood pressure measurements compared with baseline (BAS1). Measures were taken by a certified cardiologist using a Doppler device. To avoid bias in the recordings, these measurements were consistently taken before any blood was collected during each study period. To follow the ACVIM consensus panel guidelines for assessing hypertension48 and ensure accuracy, five consecutive and consistent SBP measurements were obtained from each subject. These values were then averaged to calculate an individual estimate of SBP. (B) NT-proBNP concentrations significantly increased at BAS2, with two dogs presenting values exceeding 900 pmol/L, a level commonly associated with structural heart disease in canines94,95. Box plots represent the 25th, 50th and 75th percentile of the data ± 1.5 IQR (interquartile range). •: 0.01 < P ≤ 0.05; •••: P ≤ 0.001. Summary box plots produced using the ggplot2 package in R version 4.2.2.

NT-proBNP

NT-proBNP levels significantly increased at BAS2, as shown by the change from baseline (BAS1 250.0 [250.0–401.0] pmol/L) to post-WD (BAS2 460.5 [330.0–750.0] pmol/L) (P < 0.001) (Fig. 5B). Notably, two dogs exhibited NT-proBNP concentrations exceeding 900 pmol/L.

Renin-angiotensin aldosterone system (RAAS)

Our analysis revealed a slight downward trend in biomarkers in both the traditional and alternative arms of the RAAS, though this trend was not statistically significant. This included reductions in plasma renin activity (PRA–S), Angiotensin I (Ang I (1–10)), Angiotensin II (Ang II (1–8)), Angiotensin III (Ang III (2–8)), Angiotensin IV (Ang IV (3–8)), Angiotensin 1–7 (Ang1–7), and Angiotensin 1–5 (Ang1–5). Aldosterone data was not available for statistical analysis, as over 45% of the samples had analyte levels below the lower limit of quantification. A comprehensive overview of the RAAS biomarker profile is provided in Table 3.Table 3 Effect of the western diet model on biomarkers of the Renin-angiotensin aldosterone system (RAAS).

Variable	BAS1	BAS2	P-value	
Ang I (1–10)	100.7 (70.7–114.5)	71.6 (40.3–102.3)	0.30	
Ang II (1–8)	68.8 (40.8–81.3)	45.4 (25.4–91.7)	0.62	
Ang III (2–8)	14.8 (8.4–15.4)	11.0 (7.7–12.3)	0.68	
Ang IV (3–8)	13.7 (10.3–15.8)	7.6 (5.5–11.6)	0.11	
Ang (1–7)	25.5 (11.7–35.2)	17.1 (9.0–19.0)	0.42	
Ang (1–5)	57.9 (34.7–70.6)	35.4 (25.1–54.2)	0.30	
ACE–S	0.68 (0.57–0.72)	0.64 (0.52–0.68)	0.73	
PRA–S	176.8 (121.8–194.5)	106.9 (67.5–196.5)	0.42	
ALT–S	0.34 (0.28–0.38)	0.32 (0.27–0.39)	0.62	
Pharmacodynamic changes in both the classical and alternative arm of the RAAS after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber Western diet (WD), including: Angiotensin I (Ang I (1–10)), Angiotensin II (Ang II (1–8)), Angiotensin III (Ang III (2–8)), Angiotensin IV (Ang IV (3–8)), Angiotensin 1–7 (Ang1–7), and Angiotensin 1–5 (Ang1–5). Markers for renin (PRA–S) and angiotensin-converting enzyme (ACE–S) based on angiotensin were obtained from Ang II (1–8) and Ang I (1–10) levels by calculating their sum and ratio, respectively56. Renin-independent alternative RAAS activation (ALT–S) was calculated using the formula [(Ang 1–7 + Ang 1–5) / (Ang I + Ang II + Ang 1–7 + Ang 1–5)], as previously described57.

Total cholesterol, triglycerides and lipoproteins

Figure 6 summarizes the impact of the WD on total cholesterol, HDL-cholesterol, and LDL-cholesterol. After ten weeks of feeding with the WD, there was a 44.0% increase in total cholesterol concentrations (from BAS1 130.0 [125.0–145.0] mg/dL to BAS2 187.5 [173.0–219.0] mg/dL, P < 0.001), along with a significant reduction in the AUC percentage of HDL-cholesterol (from BAS1 84.2 [80.0–85.6] % to BAS2 81.1 [73.8–83.1] %, P < 0.001) and a 26.8% elevation in the AUC percentage of LDL-cholesterol (from BAS1 14.5 [13.0–17.0] % to BAS2 18.0 [15.5–24.5] %, P < 0.001). Looking at the distribution of the absolute values for each lipoprotein fraction, the absolute HDL-cholesterol concentrations increased from BAS1 (6,977.7 [6,091.7–7,319.3] fluorescence intensity (FI)) to BAS2 (8,029.1 [6,998.5–8,346.4] FI) (P = 0.008). However, this increase was more pronounced for the absolute LDL-cholesterol concentrations (BAS1 1,206.5 [976.8–1,505.8] FI vs. BAS2 1,857.2 [1,293.9–2,467.8] FI, P < 0.001), suggesting that the WD increased total cholesterol and caused a shift from HDL-cholesterol to LDL-cholesterol. The detailed lipoprotein profiles, including levels at both baseline (BAS1) and post-WD feeding (BAS2), along with their statistical significance, are presented in Table 4. Overall, besides the changes in the AUC percentages of total HDL and total LDL-cholesterol, the WD caused a significant decrease in HDL 2a (P < 0.001), which are larger and less dense subfractions of HDL-cholesterol. Additionally, the WD induced a significant increase in LDL 3 and LDL 4 (P < 0.001), which are small and dense subfractions of LDL-cholesterol. Notably, these changes were not accompanied by significant alterations in serum triglyceride concentrations (BAS1 38.0 [33.0–45.0] mg/dL vs. BAS2 37.5 [34.0–48.0] mg/dL, P = 0.54).Fig. 6 Temporal changes in total cholesterol, HLD-cholesterol and LDL-cholesterol after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber western diet. Circulating levels of cholesterol were significantly increased (+ 44.2%) after ten weeks of feeding with the isocaloric WD. Notably, this change was accompanied by a significant reduction in HDL-cholesterol and a 26.8% elevation in LDL-cholesterol. Box plots represent the 25th, 50th and 75th percentile of the data ± 1.5 IQR (interquartile range). •••: P ≤ 0.001. Summary box plots produced using the ggplot2 package in R version 4.2.2.

Table 4 Effect of the western diet model on circulating lipoprotein fractions.

Variable	BAS1	BAS2	P-value	
HDL 2a (AUC%)	28.3 (26.4–28.8)	24.7 (21.8–27.1)	 < 0.001	
HDL 2b (AUC%)	21.4 (18.4–23.3)	21.1 (19.2–22.2)	0.39	
HDL 3a (AUC%)	25.1 (23.2–27.9)	24.6 (22.4–26.2)	0.14	
HDL 3b (AUC%)	7.1 (6.0–8.0)	7.4 (6.5–8.7)	0.13	
HDL 3c (AUC%)	1.2 (1.0–1.3)	1.3 (1.0–1.5)	0.61	
HDL total (AUC%)	84.2 (80.0–85.6)	81.1 (73.8–83.1)	 < 0.001	
LDL 1 (AUC%)	0.6 (0.5–0.8)	0.6 (0.5–0.7)	0.44	
LDL 2 (AUC%)	1.4 (1.2–1.5)	1.5 (1.2–1.7)	0.30	
LDL 3 (AUC%)	2.6 (2.4–3.5)	4.8 (3.9–6.9)	 < 0.001	
LDL 4 (AUC%)	4.1 (3.7–4.9)	5.2 (4.4–6.8)	 < 0.001	
LDL 5 (AUC%)	6.1 (4.9–6.7)	6.2 (5.0–7.4)	0.26	
LDL total (AUC%)	14.5 (13.0–17.0)	18.0 (15.5–24.5)	 < 0.001	
Total values for HDL and LDL are indicated in bold.

Lipoprotein profiles were produced by plotting the average intensity of fluorescence on the y-axis, while the actual centrifuge tube coordinates (mm) served as the x-axis. A unique numbering system was established for statistical examination. The area under the curve (AUC) of the total fluorescence trace and each segment were used to determine the total lipoprotein intensity and fractional intensities, respectively. Moreover, AUCs were calculated for high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs), based on their density intervals. These AUC values were normalized using the total AUC and expressed as percentage, as previously presented by Minamoto et al.50.

Oxidative stress

Antioxidant status

Overall, the effect of the WD on antioxidant markers was mild, with no significant changes in CUPRAC, FRAP, TEAC, and Thiol values. In contrast, PON-1 levels significantly decreased at BAS2 compared to BAS1 (BAS1 4.2 [3.7 to 4.4] IU/mL vs. BAS2 3.8 [3.6–4.0] IU/mL, P = 0.004), and GPx activity increased significantly at BAS2 (BAS1 6460.0 [5448.0–7764.0] U/L vs. BAS2 8,432.0 [6964.0–8852.0] U/L, P < 0.001). These effects are summarized in Fig. 7A.Fig. 7 Temporal changes in antioxidant (A) and oxidant (B) stress markers after ten weeks of feeding with a high-fat, high-monosaccharide, low-fiber western diet. The WD had mild effects on antioxidant markers, with no significant changes in CUPRAC, FRAP, TEAC, and Thiol values. However, PON-1 levels significantly decreased at BAS2. The impact of the WD on oxidative stress parameters was more consistent, with total oxidant status significantly increasing at BAS2. The increase extended to reactive oxygen metabolites (d-ROMs). Conversely, there was a decrease in POX-Act post-WD, but no notable effects on AOPP. Box plots represent the 25th, 50th and 75th percentile of the data ± 1.5 IQR (interquartile range). •: 0.01 < P ≤ 0.05; ••: 0.001 < P ≤ 0.01; •••: P ≤ 0.001. Summary box plots produced using the ggplot2 package in R version 4.2.2.

Oxidant status

The impact of the WD on oxidative stress parameters was more consistent, with total oxidant status significantly increasing at BAS2 (BAS1 4.8 [3.9–5.8] µmol/L vs. BAS2 7.0 [4.9–8.7] µmol/L, P = 0.018). This also extended to an increase (trend) in reactive oxygen metabolites (BAS1 21.3 [13.2–28.9] U.CARR vs. BAS2 28.8 [17.9–43.0] U.CARR, P = 0.084). Conversely, there was a decrease in POX-Act post-WD (BAS1 101.8 [79.1–114.0] µmol/L vs. BAS2 92.3 [62.1–94.2] µmol/L, P < 0.001). However, there were no discernible effects on AOPP (Fig. 7B).

Metabolomics

For all three –omics evaluated (General Metabolism, Complex Lipids, and Biogenic Amines), significant differences were observed in the metabolomes between BAS1 and BAS2.

General metabolism

Before feature selection, a clear separation between BAS1 and BAS2 was observed in the PCAs for urine, stool, and serum (Fig. 8A–C). To identify variables responsible for this separation, FS-CR was further employed74,75. FS-CR identified 48 significant metabolites in the urine samples, 37 significant metabolites in stool samples, and 10 in serum samples. The loadings of the selected variables are included in the Supplementary Information (Supplementary Figs. S1–S3, S2–S6 and S7–S9, for General Metabolism, Complex Lipids and Biogenic Amines, respectively). Following feature selection, BAS1 and BAS2 were clearly separated along PC1 for all three sample types, which explained 29.4%, 48.6%, and 82.3% of the total variance for urine, stool, and serum samples, respectively (Fig. 9A–C).Fig. 8 PCA score plots (General Metabolism) of (A) Urine, (B) Stool, and (C) Serum before feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

Fig. 9 PCA score plots (General Metabolism) of (A) Urine, (B) Stool, and (C) Serum after feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

In urine, 29 metabolites were positively correlated with BAS1, including pipecolinic acid, piperidone, cytosine, and nicotinamide (Supplementary Table 1). Additionally, 19 metabolites were strongly positively correlated with BAS2, including 2,3-dihydroxybutanoic acid (tartaric acid), arabitol, cellobiose, and glycerol (Supplementary Table 1).

In stool, seven metabolites were positively correlated with BAS1, such as cadaverine, trans-4-hydroxyproline, tryptamine, and isopalmitic acid (Supplementary Table 2). Thirty metabolites were strongly positively correlated to BAS2, including fructose, pipecolinic acid, erythrose, and 2-deoxyerythritol (Supplementary Table 2).

In serum, nine of the ten significant metabolites from FS-CR were positively correlated to BAS1, including 3-Amino-2-piperidone and 2-picolinic acid (Supplementary Table 3).

In summary, the clear separation of BAS1 and BAS2 in PCA space before feature selection suggests that the WD is causing significant, measurable changes in the general metabolism of the dogs.

Complex lipids

Prior to feature selection, no separation was observed between BAS1 and BAS2 for complex lipid urine samples (Fig. 10A). However, separation between BAS1 and BAS2 was observed along PC1 and PC2 for stool (Fig. 10B), and along PC1 for serum (Fig. 10C).Fig. 10 PCA score plots (Complex Lipids) of (A) Urine, (B) Stool, and (C) Serum before feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

With feature selection, a clear separation was achieved between BAS1 and BAS2 along PC1 for all three biospecimens (Fig. 11A–C). It is noteworthy that more than three-quarters of the total variation was explained by PC1 for stool (76.7%) and serum (82.6%) samples. With FS-CR, 36 lipids in urine, 36 in stool, and 30 in serum were selected as significant metabolites describing differences between BAS1 and BAS2.Fig. 11 PCA score plots (Complex Lipids) of (A) Urine, (B) Stool, and (C) Serum after feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

In urine, 25 lipids were positively correlated with BAS1, and 11 lipids were correlated with BAS2 (Supplementary Table 4).

In stool, 32 lipids were positively correlated with BAS1, including eicosapentaenoic acid and various triglycerides, and four lipids were correlated with BAS2, including margaric acid (Supplementary Table 5).

In serum, 14 lipids were positively correlated with BAS1, including phosphatidylcholine 38:5 and phosphatidylcholine 40:7, and 16 lipids were correlated with BAS2, including sphingomyelin (d36:2) and several phosphatidylcholines (Supplementary Table 6).

Overall, the separation of BAS1 and BAS2 stool and serum in PCA space before feature selection indicates that the WD is altering the lipidome of the dogs. Separation of BAS1 and BAS2 for complex lipids in urine was only observed after feature selection. However, 36 urinary lipids were altered as a result of the WD, suggesting that the urinary lipidome of the dogs is also affected.

Biogenic amines

Prior to feature selection, there was significant overlap between BAS1 and BAS2 for urine (Fig. 12A). However, for stool (17.6%) and serum (11.8%) samples, there was a clear separation along PC2 (Fig. 12B and C). FS-CR identified 90 significant metabolites in urine, 68 significant metabolites in stool, and 26 significant metabolites in serum. After feature selection, BAS1 and BAS2 samples were clearly separated along PC1 for all biospecimens, accounting for approximately half of the total variance in the experimental data (Fig. 13).Fig. 12 PCA score plots (Biogenic Amines) of (A) Urine, (B) Stool, and (C) Serum before feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

Fig. 13 PCA score plots (Biogenic Amines) of (A) Urine, (B) Stool, and (C) Serum after feature selection using the PLS_Toolbox software (Version 9.0; Eigenvector Research, Manson, WA).

In urine, 47 metabolites were positively correlated with BAS1, including N-acetylmannosamine, threonic acid, nicotinamide, and dopamine (Supplementary Table 7). Additionally, 43 urinary metabolites were positively correlated with BAS2, including N-methylphenylalanine, tartaric acid, and propoxyphene (Supplementary Table 7).

In stool, 51 metabolites were positively correlated with BAS1, including O-acetylsalicylic acid, caffeic acid, and 3-pyridinemethanol, while 17 metabolites were correlated with BAS2, including stachydrine and prochlorperazine (Supplementary Table 8).

In serum, 11 metabolites were positively correlated with BAS1, including 4-aminobenzoic acid and L-histidinol, while 15 metabolites were correlated with BAS2, including secnidazole, tartaric acid, and vanillin (Supplementary Table 9).

In summary, the separation of stool and serum samples between BAS1 and BAS2 before feature selection in PCA space suggests that the WD is altering the bioamine profile of the dogs. After feature selection, there was a clear separation of BAS1 and BAS2 for urine samples in PCA space, demonstrating that the WD is also altering the urinary biogenic amines profile of the dogs.

Discussion

The pleiotropic effects of SGLT-2 inhibitors and GLP-1 agonists hold the potential to target cardiorenal, hepatic and metabolic disorders using a disease model that replicates key features of MetS. Previous experiments have primarily focused on obesity-related metabolic dysfunction when examining the effects of WDs in dogs. However, there is a lack of comprehensive studies on the biological and metabolic impacts of WDs independent of obesity. In both dogs and humans, obesity causes a redistribution of adipose tissue, leading to an increase in visceral fat compared to subcutaneous fat. This change in fat distribution is independently associated with the development of MetS. This is significant as multiple reports, including analyses by Romero-Corral et al.38 and Shi et al.39 on large adult populations, have established that individuals with normal weight MetS are at an increased risk of cardiovascular diseases, metabolic dysregulation, and higher mortality rates compared to obese individuals with or without MetS. In addition, most clinical investigations on the effectiveness of SGLT-2 inhibitors for cardiovascular and renal outcomes primarily include non-obese subjects4,7,40–42. Importantly, a recent study by Adamson et al.43 demonstrated that in heart failure patients with reduced ejection fraction, the SGLT-2 inhibitor dapagliflozin effectively reduced the composite endpoint of worsening heart failure or cardiovascular death, regardless of the patient's baseline BMI. Collectively, these findings provide a compelling rationale for establishing a novel model of metabolic dysfunction that operates independently of obesity. Once established, this disease model will pave the way for in-depth studies on the pharmacodynamics of therapeutic drugs targeting cardiorenal metabolic health, including SGLT-2 inhibitors and GLP-1 agonists.

Our study maintained isocaloric conditions to isolate the effect of the diet’s composition from obesity as a confounding factor. It builds on preliminary data from Lyu et al.76, which showed a tendency towards elevated glucose concentrations in ten healthy Beagles under an isocaloric high-fat diet for six weeks. To the best of our knowledge, our research represents the first comprehensive characterization of the biological effects of a WD model, independent of obesity. By inducing MetS without causing weight gain, we have successfully developed a non-invasive, inducible, and potentially reversible preclinical model in just a few weeks. For ethical reasons and considerations related to animal welfare, it is important to emphasize that our objective was not to induce clinical symptoms of MetS in our study. Therefore, most of the observed changes reported herein remained within physiological limits. Overall, the WD was well tolerated with no reported adverse events during the study. Minor digestive issues appeared when transitioning from a regular diet to the WD, likely due to the absence of a proper weaning period between diets. However, these issues were resolved within a few days.

Hematological parameters typically remained within normal physiological limits, showing no clinically meaningful changes. The most notable variations were observed in metabolic parameters. Specifically, the WD induced a statistically significant increase in fasting blood glucose levels, approaching the upper physiological limit. This resulted in an overall increase of approximately 20% in blood glucose concentrations compared to baseline. Interestingly, this observation was accompanied by a trend towards an increase in peak insulin concentrations, which is consistent with previous literature in dogs32,36 and indicative of a perturbation in insulin sensitivity that ultimately leads to insulin resistance77. The decrease in circulating glucagon concentrations may be symptomatic of a physiological feedback mechanism to maintain glucose homeostasis in response to increased fasting blood glucose78.

Our dietary intervention also resulted in significant changes to serum chemistry parameters. These fluctuations, although still within physiological limits, demonstrate the ability of our model to greatly influence metabolism and homeostasis. Specifically, we observed a decrease in serum bicarbonate levels, which is in line with low-grade metabolic acidosis79. Our findings in dogs agree with previous data from the human literature. WDs are typically characterized by a high dietary acid load due to large amounts of animal protein and processed foods, which can exceed the kidneys' capacity to excrete the excess acid, leading to metabolic acidosis80. The concurrent increase in serum chloride concentrations reflects a state of hyperchloremic acidosis81. Overall, the association of hyperchloremic metabolic acidosis (with increased bicarbonate loss and a marked reduction in both phosphorus and potassium levels is consistent with some degree of renal tubular acidosis82–84. These findings are significant, as a recent meta-analysis, which included data from over 30,000 patients, found an association between metabolic acidosis, low bicarbonate levels, and features of MetS85. Similarly, multiple studies have shown that low levels of potassium86,87 and phosphorus88,89 were associated with an increased risk for MetS in humans.

Consistent with the definition of MetS by the National Heart, Lung, and Blood Institute (NHLBI), our diet induced a significant elevation of SBP by approximately 10 mmHg. The increase in SBP appeared to be independent of any notable changes in renin and angiotensin peptides. Interestingly, SBP was not found to increase in a previous canine study focusing on obesity-related cardiac dysfunction and MetS90, again supporting our rationale for studying the effect of western diets independently of obesity. Our study also found mild increases in NT-proBNP, although mostly within the reference range. We suspect that the increase in circulating natriuretic peptides occurred secondarily to the increase in SBP, as previously reported in the literature91,92, but it could also be indicative of cardiac stress93. Notably, some dogs showed NT-proBNP concentrations exceeding 900 pmol/L, a threshold commonly associated with structural heart disease in canines94,95.

Total cholesterol increased by approximately 45% after ten weeks. Importantly, in line with the definition of MetS, dogs fed the isocaloric WD model experienced a significant reduction in the AUC percentage of total HDL-cholesterol, along with an increase of the AUC percentage of LDL-cholesterol. Interestingly, upon examining the absolute value of each lipoprotein fraction, the absolute (untransformed) concentration of HDL-cholesterol increased after BAS1. However, this increase was more modest compared to that of LDL-cholesterol. This suggests that the WD increased total cholesterol and caused a shift from HDL to LDL-cholesterol, which is also consistent with the development of MetS. In addition to changes in total HDL and LDL-cholesterol, the WD also caused a significant decrease in the larger and less dense subfraction of HDL cholesterol (HDL 2a), with previous studies reporting a decreased risk of cardiovascular disease with higher levels of HDL2 cholesterol subfractions96,97. Consistent with these findings, the WD induced a significant increase in the small and dense subfractions of LDL cholesterol (LDL 3 and LDL 4), which are associated with a higher risk of atherosclerosis and stroke98. These changes occurred independently of any corresponding alterations in serum triglyceride concentrations, which is a variation from our preliminary data44 showing an increase in serum triglycerides in 10 healthy dogs fed with a WD for seven weeks. Although we do not have a formal explanation for the discrepancy observed between the two studies, we hypothesize that differences in the age of the dogs (with dogs from our preliminary study being overall older, with a median age of 3 years) and the significant, although modest, increase in their body weight in Iennarella-Servantez et al.44 could have contributed to the differences between studies. While surprising, this finding is also consistent with earlier research from Lahm Cardoso et al.99 which showed a strong correlation between BCS and triglyceride levels in dogs, with values approaching the upper limit of 200 mg/dL in dogs with a BCS of 8 or above (classified as “overweight” or “obese” in our study).

Our results on redox status align with previous human studies100–102. Specifically, we observed significant increases in TOS and d-ROMs at BAS2. In contrast, the effect on antioxidant markers was more nuanced and generally mild, with levels of CUPRAC, FRAP, TEAC, and Thiol remaining stable at BAS2. This is in line with the variable impact of dietary fat on systemic antioxidative stress markers in dogs. Some studies have shown no effect of carbohydrate and fat concentrations on oxidative stress biomarkers103, while others have reported an increase in antioxidant capacity, but no effect on oxidative stress markers37.

Our study highlights the comprehensive changes in the metabolome induced by the WD, including biological pathways related to general metabolism, complex lipids, and biogenic amines. These observations underscore the potential relevance of this model in studying MetS and its associated health complications. Notably, all the metabolites detected in our study were classified according to MSI Level 2 standards73. The positive correlation of nicotinamide to the baseline diet (BAS1) in both general metabolism (urine) and biogenic amines (urine) suggests that dogs had lower amounts of this essential form of vitamin B3 after ten weeks of feeding with a WD (BAS2) compared to their standard diet. This is consistent with earlier findings from Qu et al.104 reporting perturbations in nicotinamide metabolism in dogs fed a high-fat diet for twelve weeks. Nicotinamide plays a crucial role in various metabolic pathways, particularly in energy production and DNA repair105,106. Similarly, the positive correlation of glycerol to BAS2 in general metabolomics (urine) indicates that glycerol concentrations were increased during feeding with the WD. Glycerol is a key component of triglycerides and is involved in energy metabolism, especially in lipid breakdown and synthesis107. This elevation is likely related to an increased metabolism of triglycerides caused by the WD, indicating a potential shift in lipid metabolism. The positive correlation of tartaric acid (2,3-dihydrobutanoic acid) with BAS2 in multiple classes (general metabolomics in urine, biogenic amines in urine, and biogenic amines in serum) indicates that tartaric acid levels increased during the WD phase. These changes are possibly associated with the increased catabolism of the antioxidant ascorbic acid and accompany variations in oxidative stress markers highlighted above108.

A greater diversity of fatty acids was correlated with BAS1, especially in stool, indicating a wider range of fatty acid profiles in the baseline diet. This diversity is essential for energy production and cell membrane structure109. We suspect that the higher diversity of fatty acids in BAS1 is due in part to the presence of more soluble dietary fiber, which is fermented by intestinal microbiota into short chain fatty acids110. After the WD diet, there was an increase in saturated fatty acids, specifically FA 17:0 in stool lipidomics and PC 18:0. High levels of saturated fatty acids have been linked to negative health outcomes, such as cardiovascular disease111,112. Furthermore, palmitoleic acid, an omega-7 monounsaturated fatty acid, showed a positive correlation with BAS2 in stool general metabolomics. Palmitoleic acid (16:1n7) increases lipolysis, glucose uptake, and glucose utilization for energy production in white adipose cells113,114. The increase in saturated fatty acids, specifically FA 17:0 in BAS2, could suggest a shift in lipid metabolism and/or be a result of the consumption of butter and ruminant fats115. While there is a decrease in fatty acid diversity and an increase in saturated fatty acids associated with BAS2, it remains unclear whether these changes are related to MetS per se, or simply changes in stool composition caused by differences in diet composition.

In both general metabolomics (GC–MS) and LC–MS assays, several unidentified metabolites were detected. For GC–MS, this was due to spectral library matches failing to identify metabolites below the 800 threshold. Advanced data processing techniques, such as Parallel Factor Analysis, could be employed to deconvolve data and obtain cleaner spectra116,117. However, this would require a separate and dedicated study. Additionally, the bioamines assay detected several non-amine compounds due to its ability to detect compounds without an amine group. With LC–MS, the presence of unidentified metabolites could possibly be attributed to biotransformation of known metabolites, which involves the addition or removal of specific chemical moieties such as (de)-glycosylation, (de)-methylation, (de)-amination, and (de)-hydroxylation. These transformations often occur during metabolic processes118. To identify these metabolites, biotransformation analysis techniques and exploration of additional libraries and databases would be necessary. However, this is beyond the scope of this study. Despite the challenges in compound identification, the changes in metabolism observed across the three metabolomic assays are noteworthy. Additionally, several metabolites previously identified as both positively and negatively correlated with MetS in other studies, including nicotinamide, tryptophan metabolites, glycerol, and tartaric acid, were found in the metabolomics analyses presented here104–106,108,119. This suggests that the WD is inducing metabolomic changes consistent with MetS in dogs.

This study presents several limitations that are worth mentioning. First, the experiment was limited in size and did not address the potential for reversibility of the model, specifically regarding the metabolic impacts of transitioning back to a standard diet. Due to the non-invasive nature of our model, this study was primarily descriptive and did not provide in-depth mechanistic insights into how WDs affect cardiovascular-kidney-metabolic health. The study also lacks some functional data, such as the time-dependent effects of the WD on intestinal permeability and fecal microbiome composition. This was partly deliberate, as those effects have been extensively characterized previously in the literature (e.g., Ref32). Previous studies published by our consortium in dogs51–54 were conducted in the context of an activated RAAS. No elevation in PRA-S or angiotensin peptides was noted in the current study, which likely explains why many data points on aldosterone were below the lower limit of quantification, preventing statistical analysis of this biomarker. Additionally, our findings related to serum, urine and fecal metabolomics could be confounded by factors other than changes in diet composition, including differences in processing and ingredient composition between a commercial and a home-cooked diet. To minimize the impact of these potential confounding variables, we would need to conduct an experiment using two homemade diets with similar ingredients, while varying the proportions of fat, carbohydrates, and fiber to simulate the effect of a Western versus a standard diet on variables associated with MetS. At last, determining whether metabolites are changing in response to altered metabolism or simply due to changes in dietary composition using untargeted metabolomics can be challenging. Therefore, mechanism-based hypothesis testing on the metabolome would require a targeted or semi-targeted approach that focuses on specific classes of metabolites.

In summary, our isocaloric WD, designed to mimic the NHANES diet, effectively replicated key characteristics of MetS. These included elevated BP, increased fasting glucose levels, and reduced HDL-cholesterol, all independent of abdominal obesity. Additionally, the WD induced an increase in natriuretic peptide levels, along with a mild state of metabolic acidosis and significant changes in the serum, urine, and fecal metabolome. Our findings underscore the utility of this model for investigating the metabolic effects of novel antidiabetic therapies in the context of obesity-independent MetS, which will be presented in a separate manuscript. Furthermore, this research enables future translational studies that could have potential benefits for both human and veterinary medicine.

Ethical approval

Experimental procedures were approved by the Institutional Animal Care and Use Committee at Iowa State University (Protocol Number: 21-164). All methods were performed in accordance with the relevant guidelines and regulations at Iowa State University. The authors complied with ARRIVE guidelines in the completion of this study.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71202-y.

Author contributions

J.P.M.: concept and design of the study, analysis and interpretation of the data, manuscript preparation and revisions; J.L.W.: concept and design of the study, data acquisition, manuscript revisions; T.B.: data analysis and interpretation, manuscript revisions; D.K.: data analysis and interpretation, manuscript revisions; M.M.M.: data acquisition, manuscript revisions; C.Z.: concept and design of the study, funding; E.G.: concept and design of the study, funding; R.T.G.: data analysis and interpretation, manuscript revisions; P.d.l.M.: data analysis and interpretation, manuscript revisions; C.A.I.: concept of the study (NHANES WD); A.B.: concept and design of the study, manuscript revisions; S.L.N.: data analysis and interpretation, manuscript revisions; J.J.H.: data analysis and interpretation, manuscript revisions; J.S.: data analysis and interpretation, manuscript revisions; A.T.: data interpretation, manuscript revisions; J.J.C.: data analysis and interpretation, manuscript revisions; A.B.M.: data acquisition, manuscript revisions; F.Z.: data interpretation, manuscript revisions; N.S.: data interpretation, manuscript revisions; K.A.: concept and design of the study, manuscript revisions.

Funding

This study was sponsored by Ceva Sante Animale, 33500 Libourne (France).

Data availability

Research data are available upon request. Please contact Jonathan P. Mochel (jpmochel@uga.edu).

Competing interests

Mochel, Ward, Zannad, Sattar, and Allenspach act as consultants for Ceva Sante Animale. Blondel, Zemirline, and Guillot are employees of Ceva Sante Animale. All other authors do not have a conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Diabetes Prevention Program Research Group Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The diabetes prevention program outcomes study Lancet Diabetes Endocrinol. 2015 3 11 866 875 10.1016/S2213-8587(15)00291-0 26377054
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 3(11), 866–875. 10.1016/S2213-8587(15)00291-0 (2015).26377054 10.1016/S2213-8587(15)00291-0
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 09 Dec 2023.
3. Birkeland KI Bodegard J Norhammar A Kuiper JG Georgiado E Beekman-Hendriks WL Thuresson M Pignot M Herings RMC Kooy A How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT-2 inhibitors? A large European observational study Diabetes Obes. Metab. 2019 21 4 968 974 10.1111/dom.13612 30537226
Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT-2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21(4), 968–974. 10.1111/dom.13612 (2019).30537226 10.1111/dom.13612
4. Butler J Anker SD Filippatos G Khan MS Ferreira JP Pocock SJ Giannetti N Januzzi JL Piña IL Lam CSP Ponikowski P Sattar N Verma S Brueckmann M Jamal W Vedin O Peil B Zeller C Zannad F Packer M EMPEROR-reduced trial committees and investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-reduced trial Eur. Heart J. 2021 42 13 1203 1212 10.1093/eurheartj/ehaa1007 33420498
Butler, J. et al. EMPEROR-reduced trial committees and investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-reduced trial. Eur. Heart J. 42(13), 1203–1212. 10.1093/eurheartj/ehaa1007 (2021).33420498 10.1093/eurheartj/ehaa1007
5. Inzucchi SE Fitchett D Jurišić-Eržen D Woo V Hantel S Janista C Kaspers S George JT Zinman B EMPA-REG OUTCOME® Investigators Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 2020 22 4 631 639 10.1111/dom.13938 31789445
Inzucchi, S. E. et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. Diabetes Obes. Metab. 22(4), 631–639. 10.1111/dom.13938 (2020).31789445 10.1111/dom.13938
6. Kosiborod MN Abildstrøm SZ Borlaug BA Butler J Rasmussen S Davies M Hovingh GK Kitzman DW Lindegaard ML Møller DV Shah SJ Treppendahl MB Verma S Abhayaratna W Ahmed FZ Chopra V Ezekowitz J Fu M Ito H Lelonek M Melenovsky V Merkely B Núñez J Perna E Schou M Senni M Sharma K Van der Meer P von Lewinski D Wolf D Petrie MC STEP-HFpEF Trial Committees and Investigators Semaglutide in patients with heart failure with preserved ejection fraction and obesity N. Engl. J. Med. 2023 389 12 1069 1084 10.1056/NEJMoa2306963 37622681
Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389(12), 1069–1084. 10.1056/NEJMoa2306963 (2023).37622681 10.1056/NEJMoa2306963
7. McMurray JJV DeMets DL Inzucchi SE Køber L Kosiborod MN Langkilde AM Martinez FA Bengtsson O Ponikowski P Sabatine MS Sjöstrand M Solomon SD DAPA-HF Committees and Investigators The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics Eur. J. Heart Fail. 2019 21 11 1402 1411 10.1002/ejhf.1548 31309699
McMurray, J. J. V. et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics. Eur. J. Heart Fail. 21(11), 1402–1411. 10.1002/ejhf.1548 (2019).31309699 10.1002/ejhf.1548
8. Neal B Perkovic V Mahaffey KW de Zeeuw D Fulcher G Erondu N Shaw W Law G Desai M Matthews DR CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes N. Engl. J. Med. 2017 377 7 644 657 10.1056/NEJMoa1611925 28605608
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657. 10.1056/NEJMoa1611925 (2017).28605608 10.1056/NEJMoa1611925
9. Packer M Butler J Filippatos G Zannad F Ferreira JP Zeller C Brueckmann M Jamal W Pocock SJ Anker SD EMPEROR Trial Committees and Investigators Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure Eur. J. Heart Fail. 2020 22 12 2393 2398 10.1002/ejhf.2065 33251659
Packer, M. et al. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. Eur. J. Heart Fail. 22(12), 2393–2398. 10.1002/ejhf.2065 (2020).33251659 10.1002/ejhf.2065
10. Persson F Nyström T Jørgensen ME Carstensen B Gulseth HL Thuresson M Fenici P Nathanson D Eriksson JW Norhammar A Bodegard J Birkeland KI Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study Diabetes Obes. Metab. 2018 20 2 344 351 10.1111/dom.13077 28771923
Persson, F. et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes. Metab. 20(2), 344–351. 10.1111/dom.13077 (2018).28771923 10.1111/dom.13077
11. Zinman B Wanner C Lachin JM Fitchett D Bluhmki E Hantel S Mattheus M Devins T Johansen OE Woerle HJ Broedl UC Inzucchi SE EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N. Engl. J. Med. 2015 373 22 2117 2128 10.1056/NEJMoa1504720 26378978
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128. 10.1056/NEJMoa1504720 (2015).26378978 10.1056/NEJMoa1504720
12. Ndumele CE Rangaswami J Chow SL Neeland IJ Tuttle KR Khan SS Coresh J Mathew RO Baker-Smith CM Carnethon MR Despres JP Ho JE Joseph JJ Kernan WN Khera A Kosiborod MN Lekavich CL Lewis EF Lo KB Ozkan B Palaniappan LP Patel SS Pencina MJ Powell-Wiley TM Sperling LS Virani SS Wright JT Rajgopal Singh R Elkind MSV American Heart Association Cardiovascular-kidney-metabolic health: A presidential advisory from the American heart association Circulation 2023 10.1161/CIR.0000000000001184 37950677
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American heart association. Circulation10.1161/CIR.0000000000001184 (2023).37950677 10.1161/CIR.0000000000001184
13. Grundy SM Cleeman JI Daniels SR Donato KA Eckel RH Franklin BA Gordon DJ Krauss RM Savage PJ Smith SC Jr Spertus JA Costa F American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement Circulation 2005 112 17 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765
Grundy, S. M. et al. American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement. Circulation 112(17), 2735–2752. 10.1161/CIRCULATIONAHA.105.169404 (2005).16157765 10.1161/CIRCULATIONAHA.105.169404
14. Newsome PN Ambery P Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver J. Hepatol. 2023 79 1557 1565 10.1016/j.jhep.2023.07.033 37562748
Newsome, P. N. & Ambery, P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J. Hepatol. 79, 1557–1565. 10.1016/j.jhep.2023.07.033 (2023).37562748 10.1016/j.jhep.2023.07.033
15. Jacob JA Researchers turn to canine clinical trials to advance cancer therapies JAMA 2016 315 15 1550 1552 10.1001/jama.2016.0082 27027696
Jacob, J. A. Researchers turn to canine clinical trials to advance cancer therapies. JAMA 315(15), 1550–1552. 10.1001/jama.2016.0082 (2016) (PMID: 27027696).27027696 10.1001/jama.2016.0082
16. Seok J Warren HS Cuenca AG Mindrinos MN Baker HV Xu W Richards DR McDonald-Smith GP Gao H Hennessy L Finnerty CC López CM Honari S Moore EE Minei JP Cuschieri J Bankey PE Johnson JL Sperry J Nathens AB Billiar TR West MA Jeschke MG Klein MB Gamelli RL Gibran NS Brownstein BH Miller-Graziano C Calvano SE Mason PH Cobb JP Rahme LG Lowry SF Maier RV Moldawer LL Herndon DN Davis RW Xiao W Tompkins RG Inflammation and Host Response to Injury, Large Scale Collaborative Research Program Genomic responses in mouse models poorly mimic human inflammatory diseases Proc. Natl. Acad. Sci. U. S. A. 2013 110 9 3507 3512 10.1073/pnas.1222878110 23401516
Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110(9), 3507–3512. 10.1073/pnas.1222878110 (2013).23401516 10.1073/pnas.1222878110
17. Waring MJ Arrowsmith J Leach AR Leeson PD Mandrell S Owen RM Pairaudeau G Pennie WD Pickett SD Wang J Wallace O Weir A An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat. Rev. Drug Discov. 2015 14 7 475 486 10.1038/nrd4609 26091267
Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14(7), 475–486. 10.1038/nrd4609 (2015).26091267 10.1038/nrd4609
18. Zushin PH Mukherjee S Wu JC FDA modernization act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches J. Clin. Invest. 2023 133 21 e175824 10.1172/JCI175824 37909337
Zushin, P. H., Mukherjee, S. & Wu, J. C. FDA modernization act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J. Clin. Invest. 133(21), e175824. 10.1172/JCI175824 (2023).37909337 10.1172/JCI175824
19. Gilmore KM Greer KA Why is the dog an ideal model for aging research? Exp. Gerontol. 2015 71 14 20 10.1016/j.exger.2015.08.008 26325590
Gilmore, K. M. & Greer, K. A. Why is the dog an ideal model for aging research?. Exp. Gerontol. 71, 14–20. 10.1016/j.exger.2015.08.008 (2015) (Epub 2015 Aug 29 PMID: 26325590).26325590 10.1016/j.exger.2015.08.008
20. Gordon I Paoloni M Mazcko C Khanna C The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway PLoS Med. 2009 6 10 e1000161 10.1371/journal.pmed.1000161 19823573
Gordon, I., Paoloni, M., Mazcko, C. & Khanna, C. The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6(10), e1000161. 10.1371/journal.pmed.1000161 (2009).19823573 10.1371/journal.pmed.1000161
21. Kaeberlein M Creevy KE Promislow DE The dog aging project: Translational geroscience in companion animals Mamm. Genome 2016 27 7–8 279 288 10.1007/s00335-016-9638-7 27143112
Kaeberlein, M., Creevy, K. E. & Promislow, D. E. The dog aging project: Translational geroscience in companion animals. Mamm. Genome 27(7–8), 279–288. 10.1007/s00335-016-9638-7 (2016).27143112 10.1007/s00335-016-9638-7
22. Kopper JJ Iennarella-Servantez C Jergens AE Sahoo DK Guillot E Bourgois-Mochel A Martinez MN Allenspach K Mochel JP Harnessing the biology of canine intestinal organoids to heighten understanding of inflammatory bowel disease pathogenesis and accelerate drug discovery: A one health approach Front. Toxicol. 2021 10 3 773953 10.3389/ftox.2021.773953
Kopper, J. J. et al. Harnessing the biology of canine intestinal organoids to heighten understanding of inflammatory bowel disease pathogenesis and accelerate drug discovery: A one health approach. Front. Toxicol. 10(3), 773953. 10.3389/ftox.2021.773953 (2021).10.3389/ftox.2021.773953
23. Masters AK Berger DJ Ware WA Langenfeld NR Coetzee JF Mochel JPM Ward JL Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs Am. J. Vet. Res. 2018 79 4 411 423 10.2460/ajvr.79.4.411 29583045
Masters, A. K. et al. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs. Am. J. Vet. Res. 79(4), 411–423. 10.2460/ajvr.79.4.411 (2018) (PMID: 29583045).29583045 10.2460/ajvr.79.4.411
24. Sebbag L Mochel JP An eye on the dog as the scientist’s best friend for translational research in ophthalmology: Focus on the ocular surface Med. Res. Rev. 2020 40 6 2566 2604 10.1002/med.21716 32735080
Sebbag, L. & Mochel, J. P. An eye on the dog as the scientist’s best friend for translational research in ophthalmology: Focus on the ocular surface. Med. Res. Rev. 40(6), 2566–2604. 10.1002/med.21716 (2020).32735080 10.1002/med.21716
25. Xenoulis PG Steiner JM Lipid metabolism and hyperlipidemia in dogs Vet. J. 2010 183 1 12 21 10.1016/j.tvjl.2008.10.011 19167915
Xenoulis, P. G. & Steiner, J. M. Lipid metabolism and hyperlipidemia in dogs. Vet. J. 183(1), 12–21. 10.1016/j.tvjl.2008.10.011 (2010).19167915 10.1016/j.tvjl.2008.10.011
26. Kleinert M Clemmensen C Hofmann SM Moore MC Renner S Woods SC Huypens P Beckers J de Angelis MH Schürmann A Bakhti M Klingenspor M Heiman M Cherrington AD Ristow M Lickert H Wolf E Havel PJ Müller TD Tschöp MH Animal models of obesity and diabetes mellitus Nat. Rev. Endocrinol. 2018 14 3 140 162 10.1038/nrendo.2017.161 29348476
Kleinert, M. et al. Animal models of obesity and diabetes mellitus. Nat. Rev. Endocrinol. 14(3), 140–162. 10.1038/nrendo.2017.161 (2018).29348476 10.1038/nrendo.2017.161
27. Yin W Carballo-Jane E McLaren DG Mendoza VH Gagen K Geoghagen NS McNamara LA Gorski JN Eiermann GJ Petrov A Wolff M Tong X Wilsie LC Akiyama TE Chen J Thankappan A Xue J Ping X Andrews G Wickham LA Gai CL Trinh T Kulick AA Donnelly MJ Voronin GO Rosa R Cumiskey AM Bekkari K Mitnaul LJ Puig O Chen F Raubertas R Wong PH Hansen BC Koblan KS Roddy TP Hubbard BK Strack AM Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia J. Lipid Res. 2012 53 1 51 65 10.1194/jlr.M019927 22021650
Yin, W. et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 53(1), 51–65. 10.1194/jlr.M019927 (2012).22021650 10.1194/jlr.M019927
28. Mochel JP Teng CH Peyrou M Giraudel J Danhof M Rigel DF Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation Eur. J. Pharm. Sci. 2019 1 128 103 111 10.1016/j.ejps.2018.11.037
Mochel, J. P. et al. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur. J. Pharm. Sci. 1(128), 103–111. 10.1016/j.ejps.2018.11.037 (2019).10.1016/j.ejps.2018.11.037
29. Mochel JP Danhof M Chronobiology and pharmacologic modulation of the renin-angiotensin-aldosterone system in dogs: What have we learned? Rev. Physiol. Biochem. Pharmacol. 2015 169 43 69 10.1007/112_2015_27 26428686
Mochel, J. P. & Danhof, M. Chronobiology and pharmacologic modulation of the renin-angiotensin-aldosterone system in dogs: What have we learned?. Rev. Physiol. Biochem. Pharmacol. 169, 43–69. 10.1007/112_2015_27 (2015) (PMID: 26428686).26428686 10.1007/112_2015_27
30. Mochel JP Fink M Peyrou M Soubret A Giraudel JM Danhof M Pharmacokinetic/pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs Pharm. Res. 2015 32 6 1931 1946 10.1007/s11095-014-1587-9 25446774
Mochel, J. P. et al. Pharmacokinetic/pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs. Pharm. Res. 32(6), 1931–1946. 10.1007/s11095-014-1587-9 (2015).25446774 10.1007/s11095-014-1587-9
31. Schneider B Balbas-Martinez V Jergens AE Troconiz IF Allenspach K Mochel JP Model-based reverse translation between veterinary and human medicine: The one health initiative CPT Pharmacometrics Syst. Pharmacol. 2018 7 2 65 68 10.1002/psp4.12262 29178333
Schneider, B. et al. Model-based reverse translation between veterinary and human medicine: The one health initiative. CPT Pharmacometrics Syst. Pharmacol. 7(2), 65–68. 10.1002/psp4.12262 (2018).29178333 10.1002/psp4.12262
32. Moinard A Payen C Ouguerram K André A Hernandez J Drut A Biourge VC Suchodolski JS Flanagan J Nguyen P Leray V Effects of high-fat diet at two energetic levels on fecal microbiota, colonic barrier, and metabolic parameters in dogs Front. Vet. Sci. 2020 25 7 566282 10.3389/fvets.2020.566282
Moinard, A. et al. Effects of high-fat diet at two energetic levels on fecal microbiota, colonic barrier, and metabolic parameters in dogs. Front. Vet. Sci. 25(7), 566282. 10.3389/fvets.2020.566282 (2020).10.3389/fvets.2020.566282
33. Xue J Lu Y Zou T Shi W Wang S Cheng X Wan J Chen Y Wang M Wang Q Yang X Ding M Qi Z Ding Y Hu M Zhang X Li H Hu Y A protein- and fiber-rich diet with astaxanthin alleviates high-fat diet-induced obesity in beagles Front. Nutr. 2022 24 9 1019615 10.3389/fnut.2022.1019615
Xue, J. et al. A protein- and fiber-rich diet with astaxanthin alleviates high-fat diet-induced obesity in beagles. Front. Nutr. 24(9), 1019615. 10.3389/fnut.2022.1019615 (2022).10.3389/fnut.2022.1019615
34. Peña C Suarez L Bautista-Castaño I Juste MC Carretón E Montoya-Alonso JA Effects of low-fat high-fiber diet and mitratapide on body weight reduction, blood pressure and metabolic parameters in obese dogs J. Vet. Med. Sci. 2014 76 9 1305 1308 10.1292/jvms.13-0475 24920548
Peña, C. et al. Effects of low-fat high-fiber diet and mitratapide on body weight reduction, blood pressure and metabolic parameters in obese dogs. J. Vet. Med. Sci. 76(9), 1305–1308. 10.1292/jvms.13-0475 (2014).24920548 10.1292/jvms.13-0475
35. Sun H Zhang Q Xu C Mao A Zhao H Chen M Sun W Li G Zhang T Different diet energy levels alter body condition, glucolipid metabolism, fecal microbiota and metabolites in adult beagle dogs Metabolites 2023 13 4 554 10.3390/metabo13040554 37110212
Sun, H. et al. Different diet energy levels alter body condition, glucolipid metabolism, fecal microbiota and metabolites in adult beagle dogs. Metabolites 13(4), 554. 10.3390/metabo13040554 (2023).37110212 10.3390/metabo13040554
36. Tvarijonaviciute A Ceron JJ Holden SL Cuthbertson DJ Biourge V Morris PJ German AJ Obesity-related metabolic dysfunction in dogs: A comparison with human metabolic syndrome BMC Vet. Res. 2012 28 8 147 10.1186/1746-6148-8-147
Tvarijonaviciute, A. et al. Obesity-related metabolic dysfunction in dogs: A comparison with human metabolic syndrome. BMC Vet. Res. 28(8), 147. 10.1186/1746-6148-8-147 (2012).10.1186/1746-6148-8-147
37. Vecchiato CG Golinelli S Pinna C Pilla R Suchodolski JS Tvarijonaviciute A Rubio CP Dorato E Delsante C Stefanelli C Pagani E Fracassi F Biagi G Fecal microbiota and inflammatory and antioxidant status of obese and lean dogs, and the effect of caloric restriction Front. Microbiol. 2023 12 13 1050474 10.3389/fmicb.2022.1050474
Vecchiato, C. G. et al. Fecal microbiota and inflammatory and antioxidant status of obese and lean dogs, and the effect of caloric restriction. Front. Microbiol. 12(13), 1050474. 10.3389/fmicb.2022.1050474 (2023).10.3389/fmicb.2022.1050474
38. Romero-Corral A Somers VK Sierra-Johnson J Korenfeld Y Boarin S Korinek J Jensen MD Parati G Lopez-Jimenez F Normal weight obesity: A risk factor for cardiometabolic dysregulation and cardiovascular mortality Eur. Heart J. 2010 31 6 737 746 10.1093/eurheartj/ehp487 19933515
Romero-Corral, A. et al. Normal weight obesity: A risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur. Heart J. 31(6), 737–746. 10.1093/eurheartj/ehp487 (2010).19933515 10.1093/eurheartj/ehp487
39. Shi TH Wang B Natarajan S The influence of metabolic syndrome in predicting mortality risk among US adults: Importance of metabolic syndrome even in adults with normal weight Prev. Chronic Dis. 2020 21 17 E36 10.5888/pcd17.200020
Shi, T. H., Wang, B. & Natarajan, S. The influence of metabolic syndrome in predicting mortality risk among US adults: Importance of metabolic syndrome even in adults with normal weight. Prev. Chronic Dis. 21(17), E36. 10.5888/pcd17.200020 (2020).10.5888/pcd17.200020
40. EMPA-KIDNEY Collaborative Group Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial Nephrol. Dial. Transpl. 2022 37 7 1317 1329 10.1093/ndt/gfac040
EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transpl. 37(7), 1317–1329. 10.1093/ndt/gfac040 (2022).10.1093/ndt/gfac040
41. Oyama K Raz I Cahn A Kuder J Murphy SA Bhatt DL Leiter LA McGuire DK Wilding JPH Park KS Goudev A Diaz R Špinar J Gause-Nilsson IAM Mosenzon O Sabatine MS Wiviott SD Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial Eur. Heart J. 2022 43 31 2958 2967 10.1093/eurheartj/ehab530 34427295
Oyama, K. et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur. Heart J. 43(31), 2958–2967. 10.1093/eurheartj/ehab530 (2022) (PMID: 34427295).34427295 10.1093/eurheartj/ehab530
42. Wheeler DC Stefansson BV Batiushin M Bilchenko O Cherney DZI Chertow GM Douthat W Dwyer JP Escudero E Pecoits-Filho R Furuland H Górriz JL Greene T Haller H Hou FF Kang SW Isidto R Khullar D Mark PB McMurray JJV Kashihara N Nowicki M Persson F Correa-Rotter R Rossing P Toto RD Umanath K Van Bui P Wittmann I Lindberg M Sjöström CD Langkilde AM Heerspink HJL The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics Nephrol. Dial. Transp. 2020 35 10 1700 1711 10.1093/ndt/gfaa234
Wheeler, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol. Dial. Transp. 35(10), 1700–1711. 10.1093/ndt/gfaa234 (2020).10.1093/ndt/gfaa234
43. Adamson C Jhund PS Docherty KF Bělohlávek J Chiang CE Diez M Drożdż J Dukát A Howlett J Ljungman CEA Petrie MC Schou M Inzucchi SE Køber L Kosiborod MN Martinez FA Ponikowski P Sabatine MS Solomon SD Bengtsson O Langkilde AM Lindholm D Sjöstrand M McMurray JJV Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index Eur. J. Heart Fail. 2021 23 10 1662 1672 10.1002/ejhf.2308 34272791
Adamson, C. et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur. J. Heart Fail. 23(10), 1662–1672. 10.1002/ejhf.2308 (2021).34272791 10.1002/ejhf.2308
44. Iennarella-Servantez CA Kathrani A Sahoo DK Long EK Zdyrski C Gabriel V Bedos L Mao S Bourgois-Mochel A Resop MJ Rund LR Rossoni Serao M Jergens AE Mochel JP Allenspach K Diet-induced clinical responsiveness of translational dog model for human western diet (WD)-related disease research J. Anim. Sci. 2021 99 3 58 59 10.1093/jas/skab235.104
Iennarella-Servantez, C. A. et al. Diet-induced clinical responsiveness of translational dog model for human western diet (WD)-related disease research. J. Anim. Sci. 99(3), 58–59. 10.1093/jas/skab235.104 (2021).10.1093/jas/skab235.104
45. German AJ Holden SL Moxham GL Holmes KL Hackett RM Rawlings JM A simple, reliable tool for owners to assess the body condition of their dog or cat J. Nutr. 2006 136 7 Suppl 2031S 2033S 10.1093/jn/136.7.2031S 16772488
German, A. J. et al. A simple, reliable tool for owners to assess the body condition of their dog or cat. J. Nutr. 136(7 Suppl), 2031S-2033S. 10.1093/jn/136.7.2031S (2006) (PMID: 16772488).16772488 10.1093/jn/136.7.2031S
46. National Health and Nutrition Examination Survey. (NHANES 2015–2016: Males and Females over 20 years). https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/temp-wweia-usual-intake-data-tables/.
47. National Research Council Nutrient Requirements of Dogs and Cats 2006 Washington The National Academies Press
National Research Council. Nutrient Requirements of Dogs and Cats (The National Academies Press, Washington, 2006).
48. Acierno MJ Brown S Coleman AE Jepson RE Papich M Stepien RL Syme HM ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats J. Vet. Intern. Med. 2018 32 6 1803 1822 10.1111/jvim.15331 30353952
Acierno, M. J. et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J. Vet. Intern. Med. 32(6), 1803–1822. 10.1111/jvim.15331 (2018).30353952 10.1111/jvim.15331
49. Larner, C. D. High performance lipoprotein profiling for cardiovascular risk assessment. PhD thesis, Texas A&M University (2012).
50. Minamoto T Walzem RL Hamilton AJ Hill SL Payne HR Lidbury JA Suchodolski JS Steiner JM Altered lipoprotein profiles in cats with hepatic lipidosis J. Feline Med. Surg. 2019 21 4 363 372 10.1177/1098612X18780060 29860906
Minamoto, T. et al. Altered lipoprotein profiles in cats with hepatic lipidosis. J. Feline Med. Surg. 21(4), 363–372. 10.1177/1098612X18780060 (2019).29860906 10.1177/1098612X18780060
51. Schneider BK Ward J Sotillo S Garelli-Paar C Guillot E Prikazsky M Mochel JP Breakthrough: A first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine Sci. Rep. 2023 13 1 3300 10.1038/s41598-023-30453-x 36843132
Schneider, B. K. et al. Breakthrough: A first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine. Sci. Rep. 13(1), 3300. 10.1038/s41598-023-30453-x (2023).36843132 10.1038/s41598-023-30453-x
52. Sotillo S Ward JL Guillot E Domenig O Yuan L Smith JS Gabriel V Iennarella-Servantez CA Mochel JP Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs Sci. Rep. 2023 13 1 2684 10.1038/s41598-023-29771-x 36792677
Sotillo, S. et al. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs. Sci. Rep. 13(1), 2684. 10.1038/s41598-023-29771-x (2023).36792677 10.1038/s41598-023-29771-x
53. Ward JL Chou YY Yuan L Dorman KS Mochel JP Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease J. Vet. Intern. Med. 2021 35 5 2102 2111 10.1111/jvim.16236 34387901
Ward, J. L., Chou, Y. Y., Yuan, L., Dorman, K. S. & Mochel, J. P. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease. J. Vet. Intern. Med. 35(5), 2102–2111. 10.1111/jvim.16236 (2021).34387901 10.1111/jvim.16236
54. Ward JL Guillot E Domenig O Ware WA Yuan L Mochel JP Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy J. Vet. Intern. Med. 2022 36 3 897 909 10.1111/jvim.16401 35285549
Ward, J. L. et al. Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. J. Vet. Intern. Med. 36(3), 897–909. 10.1111/jvim.16401 (2022).35285549 10.1111/jvim.16401
55. Domenig O Manzel A Grobe N Königshausen E Kaltenecker CC Kovarik JJ Stegbauer J Gurley SB van Oyen D Antlanger M Bader M Motta-Santos D Santos RA Elased KM Säemann MD Linker RA Poglitsch M Neprilysin is a mediator of alternative renin-angiotensin-system activation in the Murine and human kidney Sci. Rep. 2016 21 6 33678 10.1038/srep33678
Domenig, O. et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the Murine and human kidney. Sci. Rep. 21(6), 33678. 10.1038/srep33678 (2016).10.1038/srep33678
56. Guo Z Poglitsch M McWhinney BC Ungerer JPJ Ahmed AH Gordon RD Wolley M Stowasser M Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism Clin. Chem. 2020 66 3 483 492 10.1093/clinchem/hvaa001 32068832
Guo, Z. et al. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism. Clin. Chem. 66(3), 483–492. 10.1093/clinchem/hvaa001 (2020) (PMID: 32068832).32068832 10.1093/clinchem/hvaa001
57. Zoufaly A Poglitsch M Aberle JH Hoepler W Seitz T Traugott M Grieb A Pawelka E Laferl H Wenisch C Neuhold S Haider D Stiasny K Bergthaler A Puchhammer-Stoeckl E Mirazimi A Montserrat N Zhang H Slutsky AS Penninger JM Human recombinant soluble ACE2 in severe COVID-19 Lancet Respir. Med. 2020 8 11 1154 1158 10.1016/S2213-2600(20)30418-5 33131609
Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8(11), 1154–1158. 10.1016/S2213-2600(20)30418-5 (2020).33131609 10.1016/S2213-2600(20)30418-5
58. González-Arostegui LG Muñoz-Prieto A Tvarijonaviciute A Cerón JJ Rubio CP Measurement of redox biomarkers in the whole blood and red blood cell lysates of dogs Antioxidants (Basel) 2022 11 2 424 10.3390/antiox11020424 35204305
González-Arostegui, L. G., Muñoz-Prieto, A., Tvarijonaviciute, A., Cerón, J. J. & Rubio, C. P. Measurement of redox biomarkers in the whole blood and red blood cell lysates of dogs. Antioxidants (Basel) 11(2), 424. 10.3390/antiox11020424 (2022).35204305 10.3390/antiox11020424
59. Campos C Guzmán R López-Fernández E Casado A Evaluation of the copper(II) reduction assay using bathocuproinedisulfonic acid disodium salt for the total antioxidant capacity assessment: The CUPRAC-BCS assay Anal. Biochem. 2009 392 1 37 44 10.1016/j.ab.2009.05.024 19464250
Campos, C., Guzmán, R., López-Fernández, E. & Casado, A. Evaluation of the copper(II) reduction assay using bathocuproinedisulfonic acid disodium salt for the total antioxidant capacity assessment: The CUPRAC-BCS assay. Anal. Biochem. 392(1), 37–44. 10.1016/j.ab.2009.05.024 (2009) (Epub 2009 May 21 PMID: 19464250).19464250 10.1016/j.ab.2009.05.024
60. Rubio CP Hernández-Ruiz J Martinez-Subiela S Tvarijonaviciute A Arnao MB Ceron JJ Validation of three automated assays for total antioxidant capacity determination in canine serum samples J. Vet. Diagn. Invest. 2016 28 6 693 698 10.1177/1040638716664939 27698166
Rubio, C. P. et al. Validation of three automated assays for total antioxidant capacity determination in canine serum samples. J. Vet. Diagn. Invest. 28(6), 693–698. 10.1177/1040638716664939 (2016).27698166 10.1177/1040638716664939
61. Benzie IF Strain JJ The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay Anal. Biochem. 1996 239 1 70 76 10.1006/abio.1996.0292 8660627
Benzie, I. F. & Strain, J. J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. Anal. Biochem. 239(1), 70–76. 10.1006/abio.1996.0292 (1996) (PMID: 8660627).8660627 10.1006/abio.1996.0292
62. Arnao MB Cano A Hernández-Ruiz J García-Cánovas F Acosta M Inhibition by L-ascorbic acid and other antioxidants of the 2.2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: A new approach for determining total antioxidant status of foods Anal. Biochem. 1996 236 2 255 261 10.1006/abio.1996.0164 8660502
Arnao, M. B., Cano, A., Hernández-Ruiz, J., García-Cánovas, F. & Acosta, M. Inhibition by L-ascorbic acid and other antioxidants of the 2.2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: A new approach for determining total antioxidant status of foods. Anal. Biochem. 236(2), 255–261. 10.1006/abio.1996.0164 (1996).8660502 10.1006/abio.1996.0164
63. Da Costa CM Dos Santos RCC Lima ES A simple automated procedure for thiol measurement in human serum samples J. Bras. Patol. Med. Lab. 2006 42 345 350 10.1590/S1676-24442006000500006
Da Costa, C. M., Dos Santos, R. C. C. & Lima, E. S. A simple automated procedure for thiol measurement in human serum samples. J. Bras. Patol. Med. Lab. 42, 345–350. 10.1590/S1676-24442006000500006 (2006).10.1590/S1676-24442006000500006
64. Tvarijonaviciute A Tecles F Caldin M Tasca S Cerón J Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs Am. J. Vet. Res. 2012 73 1 34 41 10.2460/ajvr.73.1.34 22204286
Tvarijonaviciute, A., Tecles, F., Caldin, M., Tasca, S. & Cerón, J. Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs. Am. J. Vet. Res. 73(1), 34–41. 10.2460/ajvr.73.1.34 (2012) (PMID: 22204286).22204286 10.2460/ajvr.73.1.34
65. Kapun AP Salobir J Levart A Kotnik T Svete AN Oxidative stress markers in canine atopic dermatitis Res. Vet. Sci. 2012 92 3 469 470 10.1016/j.rvsc.2011.04.014 21601227
Kapun, A. P., Salobir, J., Levart, A., Kotnik, T. & Svete, A. N. Oxidative stress markers in canine atopic dermatitis. Res. Vet. Sci. 92(3), 469–470. 10.1016/j.rvsc.2011.04.014 (2012).21601227 10.1016/j.rvsc.2011.04.014
66. Verk B Nemec Svete A Salobir J Rezar V Domanjko PA Markers of oxidative stress in dogs with heart failure J. Vet. Diagn. Invest. 2017 29 5 636 644 10.1177/1040638717711995 28580831
Verk, B., Nemec Svete, A., Salobir, J., Rezar, V. & Domanjko, P. A. Markers of oxidative stress in dogs with heart failure. J. Vet. Diagn. Invest. 29(5), 636–644. 10.1177/1040638717711995 (2017).28580831 10.1177/1040638717711995
67. Erel O A new automated colorimetric method for measuring total oxidant status Clin. Biochem. 2005 38 12 1103 1111 10.1016/j.clinbiochem.2005.08.008 16214125
Erel, O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 38(12), 1103–1111. 10.1016/j.clinbiochem.2005.08.008 (2005) (Epub 2005 Oct 7 PMID: 16214125).16214125 10.1016/j.clinbiochem.2005.08.008
68. Tatzber F Griebenow S Wonisch W Winkler R Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera Anal. Biochem. 2003 316 2 147 153 10.1016/s0003-2697(02)00652-8 12711334
Tatzber, F., Griebenow, S., Wonisch, W. & Winkler, R. Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera. Anal. Biochem. 316(2), 147–153. 10.1016/s0003-2697(02)00652-8 (2003) (PMID: 12711334).12711334 10.1016/s0003-2697(02)00652-8
69. Alberti A Bolognini L Macciantelli D Caratelli M The radical cation of N, N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples Res. Chem. Intermed. 2000 26 253 267 10.1163/156856700X00769
Alberti, A., Bolognini, L., Macciantelli, D. & Caratelli, M. The radical cation of N, N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 26, 253–267. 10.1163/156856700X00769 (2000).10.1163/156856700X00769
70. Rubio CP Tvarijonaviciute A Caldin M Hernández-Ruiz J Cerón JJ Martínez-Subiela S Tecles F Stability of biomarkers of oxidative stress in canine serum Res. Vet. Sci. 2018 121 85 93 10.1016/j.rvsc.2018.09.007 30359815
Rubio, C. P. et al. Stability of biomarkers of oxidative stress in canine serum. Res. Vet. Sci. 121, 85–93. 10.1016/j.rvsc.2018.09.007 (2018).30359815 10.1016/j.rvsc.2018.09.007
71. Witko-Sarsat V Friedlander M Capeillère-Blandin C Nguyen-Khoa T Nguyen AT Zingraff J Jungers P Descamps-Latscha B Advanced oxidation protein products as a novel marker of oxidative stress in uremia Kidney Int. 1996 49 5 1304 1313 10.1038/ki.1996.186 8731095
Witko-Sarsat, V. et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49(5), 1304–1313. 10.1038/ki.1996.186 (1996) (PMID: 8731095).8731095 10.1038/ki.1996.186
72. Matyash V Liebisch G Kurzchalia TV Shevchenko A Schwudke D Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics J. Lipid Res. 2008 49 5 1137 1146 10.1194/jlr.D700041-JLR200 18281723
Matyash, V., Liebisch, G., Kurzchalia, T. V., Shevchenko, A. & Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49(5), 1137–1146. 10.1194/jlr.D700041-JLR200 (2008).18281723 10.1194/jlr.D700041-JLR200
73. Sumner LW Amberg A Barrett D Beale MH Beger R Daykin CA Fan TW Fiehn O Goodacre R Griffin JL Hankemeier T Hardy N Harnly J Higashi R Kopka J Lane AN Lindon JC Marriott P Nicholls AW Reily MD Thaden JJ Viant MR Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI) Metabolomics 2007 3 3 211 221 10.1007/s11306-007-0082-2 24039616
Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics 3(3), 211–221. 10.1007/s11306-007-0082-2 (2007).24039616 10.1007/s11306-007-0082-2
74. Adutwum LA de la Mata AP Bean HD Hill JE Harynuk JJ Estimation of start and stop numbers for cluster resolution feature selection algorithm: An empirical approach using null distribution analysis of Fisher ratios Anal. Bioanal. Chem. 2017 409 28 6699 6708 10.1007/s00216-017-0628-8 28963623
Adutwum, L. A., de la Mata, A. P., Bean, H. D., Hill, J. E. & Harynuk, J. J. Estimation of start and stop numbers for cluster resolution feature selection algorithm: An empirical approach using null distribution analysis of Fisher ratios. Anal. Bioanal. Chem. 409(28), 6699–6708. 10.1007/s00216-017-0628-8 (2017).28963623 10.1007/s00216-017-0628-8
75. Sinkov NA Harynuk JJ Cluster resolution: A metric for automated, objective and optimized feature selection in chemometric modeling Talanta 2011 83 4 1079 1087 10.1016/j.talanta.2010.10.025 21215842
Sinkov, N. A. & Harynuk, J. J. Cluster resolution: A metric for automated, objective and optimized feature selection in chemometric modeling. Talanta 83(4), 1079–1087. 10.1016/j.talanta.2010.10.025 (2011).21215842 10.1016/j.talanta.2010.10.025
76. Lyu Y Liu D Nguyen P Peters I Heilmann RM Fievez V Hemeryck LY Hesta M Differences in metabolic profiles of healthy dogs fed a high-fat vs. a high-starch diet Front. Vet. Sci. 2022 9 801863 10.3389/fvets.2022.801863 35252418
Lyu, Y. et al. Differences in metabolic profiles of healthy dogs fed a high-fat vs. a high-starch diet. Front. Vet. Sci. 9, 801863. 10.3389/fvets.2022.801863 (2022).35252418 10.3389/fvets.2022.801863
77. Cavaghan MK Ehrmann DA Polonsky KS Interactions between insulin resistance and insulin secretion in the development of glucose intolerance J. Clin. Invest. 2000 106 3 329 333 10.1172/JCI10761 10930434
Cavaghan, M. K., Ehrmann, D. A. & Polonsky, K. S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest. 106(3), 329–333. 10.1172/JCI10761 (2000).10930434 10.1172/JCI10761
78. Rix, I., Nexøe-Larsen, C., Bergmann, N. C., Lund, A. & Knop, F. K. Glucagon Physiology. In: Feingold, K. R., Anawalt, B., Blackman, M. R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W. W., Dhatariya, K., Dungan, K., Hofland, J., Kalra, S., Kaltsas, G., Kapoor, N., Koch, C., Kopp, P., Korbonits, M., Kovacs, C. S., Kuohung, W., Laferrère, B., Levy, M., McGee, E. A., McLachlan, R., New, M., Purnell, J., Sahay, R., Shah, A. S., Singer, F., Sperling, M. A., Stratakis, C. A., Trence, D. L. & Wilson, D. P., (eds). South Dartmouth (MA): MDText.com, Inc. (2000).
79. Burger, M. & Schaller, D. J. Metabolic Acidosis. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID: 29489167 (2023).
80. Wieërs MLAJ Beynon-Cobb B Visser WJ Attaye I Dietary acid load in health and disease Pflugers Arch. 2024 476 4 427 443 10.1007/s00424-024-02910-7 38282081
Wieërs, M. L. A. J., Beynon-Cobb, B., Visser, W. J. & Attaye, I. Dietary acid load in health and disease. Pflugers Arch. 476(4), 427–443. 10.1007/s00424-024-02910-7 (2024).38282081 10.1007/s00424-024-02910-7
81. Sharma, S., Hashmi, M. F. & Aggarwal, S. Hyperchloremic Acidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2023).
82. Bamgbola OF Review of the pathophysiologic and clinical aspects of hypokalemia in children and young adults: An Update Curr. Treat Options Pediatr. 2022 8 3 96 114 10.1007/s40746-022-00240-3 37521171
Bamgbola, O. F. Review of the pathophysiologic and clinical aspects of hypokalemia in children and young adults: An Update. Curr. Treat Options Pediatr. 8(3), 96–114. 10.1007/s40746-022-00240-3 (2022).37521171 10.1007/s40746-022-00240-3
83. Batlle D Hays S Foley R Chan Y Arruda JA Kurtzman NA Proximal renal tubular acidosis and hypophosphatemia induced by arginine Adv. Exp. Med. Biol. 1982 151 239 249 10.1007/978-1-4684-4259-5_30 6817609
Batlle, D. et al. Proximal renal tubular acidosis and hypophosphatemia induced by arginine. Adv. Exp. Med. Biol. 151, 239–249. 10.1007/978-1-4684-4259-5_30 (1982) (PMID: 6817609).6817609 10.1007/978-1-4684-4259-5_30
84. Vasquez-Rios G Westrich DJ Jr Philip I Edwards JC Shieh S Distal renal tubular acidosis and severe hypokalemia: A case report and review of the literature J. Med. Case Rep. 2019 13 1 103 10.1186/s13256-019-2056-1 31023369
Vasquez-Rios, G., Westrich, D. J. Jr., Philip, I., Edwards, J. C. & Shieh, S. Distal renal tubular acidosis and severe hypokalemia: A case report and review of the literature. J. Med. Case Rep. 13(1), 103. 10.1186/s13256-019-2056-1 (2019).31023369 10.1186/s13256-019-2056-1
85. Lambert DC Kane J Slaton A Abramowitz MK Associations of metabolic syndrome and abdominal obesity with anion gap metabolic acidosis among US adults Kidney360 2022 3 11 1842 1851 10.34067/KID.0002402022 36514392
Lambert, D. C., Kane, J., Slaton, A. & Abramowitz, M. K. Associations of metabolic syndrome and abdominal obesity with anion gap metabolic acidosis among US adults. Kidney360 3(11), 1842–1851. 10.34067/KID.0002402022 (2022).36514392 10.34067/KID.0002402022
86. Stoian M Stoica V The role of distubances of phosphate metabolism in metabolic syndrome Maedica (Bucur) 2014 9 3 255 260 25705287
Stoian, M. & Stoica, V. The role of distubances of phosphate metabolism in metabolic syndrome. Maedica (Bucur) 9(3), 255–260 (2014).25705287
87. Sun K Su T Li M Xu B Xu M Lu J Liu J Bi Y Ning G Serum potassium level is associated with metabolic syndrome: A population-based study Clin. Nutr. 2014 33 3 521 527 10.1016/j.clnu.2013.07.010 23910935
Sun, K. et al. Serum potassium level is associated with metabolic syndrome: A population-based study. Clin. Nutr. 33(3), 521–527. 10.1016/j.clnu.2013.07.010 (2014).23910935 10.1016/j.clnu.2013.07.010
88. Kalaitzidis R Tsimihodimos V Bairaktari E Siamopoulos KC Elisaf M Disturbances of phosphate metabolism: Another feature of metabolic syndrome Am. J. Kidney Dis. 2005 45 5 851 858 10.1053/j.ajkd.2005.01.005 15861350
Kalaitzidis, R., Tsimihodimos, V., Bairaktari, E., Siamopoulos, K. C. & Elisaf, M. Disturbances of phosphate metabolism: Another feature of metabolic syndrome. Am. J. Kidney Dis. 45(5), 851–858. 10.1053/j.ajkd.2005.01.005 (2005) (PMID: 15861350).15861350 10.1053/j.ajkd.2005.01.005
89. Shimodaira M Okaniwa S Nakayama T Reduced serum phosphorus levels were associated with metabolic syndrome in men but not in women: A cross-sectional study among the Japanese population Ann. Nutr. Metab. 2017 71 3–4 150 156 10.1159/000480354 28881349
Shimodaira, M., Okaniwa, S. & Nakayama, T. Reduced serum phosphorus levels were associated with metabolic syndrome in men but not in women: A cross-sectional study among the Japanese population. Ann. Nutr. Metab. 71(3–4), 150–156. 10.1159/000480354 (2017).28881349 10.1159/000480354
90. Tropf M Nelson OL Lee PM Weng HY Cardiac and metabolic variables in obese dogs J. Vet. Intern. Med. 2017 31 4 1000 1007 10.1111/jvim.14775 28608635
Tropf, M., Nelson, O. L., Lee, P. M. & Weng, H. Y. Cardiac and metabolic variables in obese dogs. J. Vet. Intern. Med. 31(4), 1000–1007. 10.1111/jvim.14775 (2017).28608635 10.1111/jvim.14775
91. Hussain A Sun W Deswal A de Lemos JA McEvoy JW Hoogeveen RC Matsushita K Aguilar D Bozkurt B Virani SS Shah AM Selvin E Ndumule C Ballantyne CM Nambi V Association of NT-ProBNP, blood pressure, and cardiovascular events: The ARIC study J. Am. Coll. Cardiol. 2021 77 5 559 571 10.1016/j.jacc.2020.11.063 33538254
Hussain, A. et al. Association of NT-ProBNP, blood pressure, and cardiovascular events: The ARIC study. J. Am. Coll. Cardiol. 77(5), 559–571. 10.1016/j.jacc.2020.11.063 (2021).33538254 10.1016/j.jacc.2020.11.063
92. Jang IS Yoon WK Choi EW N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B Ir. Vet. J. 2023 76 1 3 10.1186/s13620-023-00233-0 36755290
Jang, I. S., Yoon, W. K. & Choi, E. W. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B. Ir. Vet. J. 76(1), 3. 10.1186/s13620-023-00233-0 (2023).36755290 10.1186/s13620-023-00233-0
93. Bayes-Genis A Docherty KF Petrie MC Januzzi JL Mueller C Anderson L Bozkurt B Butler J Chioncel O Cleland JGF Christodorescu R Del Prato S Gustafsson F Lam CSP Moura B Pop-Busui R Seferovic P Volterrani M Vaduganathan M Metra M Rosano G Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the heart failure association of the ESC Eur. J. Heart Fail. 2023 10.1002/ejhf.3036 38059343
Bayes-Genis, A. et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the heart failure association of the ESC. Eur. J. Heart Fail.10.1002/ejhf.3036 (2023).38059343 10.1002/ejhf.3036
94. Singletary GE Morris NA Lynne O’Sullivan M Gordon SG Oyama MA Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers J. Vet. Intern. Med. 2012 26 6 1330 1336 10.1111/j.1939-1676.2012.1000.x 22998090
Singletary, G. E., Morris, N. A., Lynne O’Sullivan, M., Gordon, S. G. & Oyama, M. A. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J. Vet. Intern. Med. 26(6), 1330–1336. 10.1111/j.1939-1676.2012.1000.x (2012).22998090 10.1111/j.1939-1676.2012.1000.x
95. Wilshaw J Rosenthal SL Wess G Dickson D Bevilacqua L Dutton E Deinert M Abrantes R Schneider I Oyama MA Gordon SG Elliott J Xia D Boswood A Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease J. Vet. Intern. Med. 2021 35 2 755 770 10.1111/jvim.16083 33645846
Wilshaw, J. et al. Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. J. Vet. Intern. Med. 35(2), 755–770. 10.1111/jvim.16083 (2021).33645846 10.1111/jvim.16083
96. Akinkuolie AO Paynter NP Padmanabhan L Mora S High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease Circ. Cardiovasc. Qual. Outcomes 2014 7 1 55 63 10.1161/CIRCOUTCOMES.113.000675 24248942
Akinkuolie, A. O., Paynter, N. P., Padmanabhan, L. & Mora, S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ. Cardiovasc. Qual. Outcomes 7(1), 55–63. 10.1161/CIRCOUTCOMES.113.000675 (2014).24248942 10.1161/CIRCOUTCOMES.113.000675
97. Superko HR Pendyala L Williams PT Momary KM King SB III Garrett BC High-density lipoprotein subclasses and their relationship to cardiovascular disease J. Clin. Lipidol. 2012 6 6 496 523 10.1016/j.jacl.2012.03.001 23312047
Superko, H. R. et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J. Clin. Lipidol. 6(6), 496–523. 10.1016/j.jacl.2012.03.001 (2012).23312047 10.1016/j.jacl.2012.03.001
98. Duan R Xue W Wang K Yin N Hao H Chu H Wang L Meng P Diao L Estimation of the LDL subclasses in ischemic stroke as a risk factor in a Chinese population BMC Neurol. 2020 20 1 414 10.1186/s12883-020-01989-6 33183255
Duan, R. et al. Estimation of the LDL subclasses in ischemic stroke as a risk factor in a Chinese population. BMC Neurol. 20(1), 414. 10.1186/s12883-020-01989-6 (2020).33183255 10.1186/s12883-020-01989-6
99. Lahm Cardoso JM Fagnani R Zaghi Cavalcante C de Souza ZM Júnior AZ da Silveira H Fertonani L Calesso JR Melussi M Pinheiro Costa H Yudi HE Blood pressure, serum glucose, cholesterol, and triglycerides in dogs with different body scores Vet. Med. Int. 2016 2016 8675283 10.1155/2016/8675283 28058131
Lahm Cardoso, J. M. et al. Blood pressure, serum glucose, cholesterol, and triglycerides in dogs with different body scores. Vet. Med. Int. 2016, 8675283. 10.1155/2016/8675283 (2016).28058131 10.1155/2016/8675283
100. Aleksandrova K Koelman L Rodrigues CE Dietary patterns and biomarkers of oxidative stress and inflammation: A systematic review of observational and intervention studies Redox Biol. 2021 42 101869 10.1016/j.redox.2021.101869 33541846
Aleksandrova, K., Koelman, L. & Rodrigues, C. E. Dietary patterns and biomarkers of oxidative stress and inflammation: A systematic review of observational and intervention studies. Redox Biol. 42, 101869. 10.1016/j.redox.2021.101869 (2021).33541846 10.1016/j.redox.2021.101869
101. Boden G Homko C Barrero CA Stein TP Chen X Cheung P Fecchio C Koller S Merali S Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men Sci. Transl. Med. 2015 7 304 304re7 10.1126/scitranslmed.aac4765 26355033
Boden, G. et al. Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men. Sci. Transl. Med. 7(304), 304re7. 10.1126/scitranslmed.aac4765 (2015).26355033 10.1126/scitranslmed.aac4765
102. Matsuzawa-Nagata N Takamura T Ando H Nakamura S Kurita S Misu H Ota T Yokoyama M Honda M Miyamoto K Kaneko S Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity Metabolism 2008 57 8 1071 1077 10.1016/j.metabol.2008.03.010 18640384
Matsuzawa-Nagata, N. et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 57(8), 1071–1077. 10.1016/j.metabol.2008.03.010 (2008) (PMID: 18640384).18640384 10.1016/j.metabol.2008.03.010
103. Chiofalo B Fazio E Lombardi P Cucinotta S Mastellone V Di Rosa AR Cravana C Effects of dietary protein and fat concentrations on hormonal and oxidative blood stress biomarkers in guide dogs during training J. Vet. Behav. 2020 37 86 92 10.1016/j.jveb.2019.12.003
Chiofalo, B. et al. Effects of dietary protein and fat concentrations on hormonal and oxidative blood stress biomarkers in guide dogs during training. J. Vet. Behav. 37, 86–92. 10.1016/j.jveb.2019.12.003 (2020).10.1016/j.jveb.2019.12.003
104. Qu W Chen Z Hu X Zou T Huang Y Zhang Y Hu Y Tian S Wan J Liao R Bai L Xue J Ding Y Hu M Zhang XJ Zhang X Zhao J Cheng X She ZG Li H Profound perturbation in the metabolome of a canine obesity and metabolic disorder model Front. Endocrinol. (Lausanne) 2022 19 13 849060 10.3389/fendo.2022.849060
Qu, W. et al. Profound perturbation in the metabolome of a canine obesity and metabolic disorder model. Front. Endocrinol. (Lausanne) 19(13), 849060. 10.3389/fendo.2022.849060 (2022).10.3389/fendo.2022.849060
105. Amjad S Nisar S Bhat AA Shah AR Frenneaux MP Fakhro K Haris M Reddy R Patay Z Baur J Bagga P Role of NAD+ in regulating cellular and metabolic signaling pathways Mol. Metab. 2021 49 101195 10.1016/j.molmet.2021.101195 33609766
Amjad, S. et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol. Metab. 49, 101195. 10.1016/j.molmet.2021.101195 (2021).33609766 10.1016/j.molmet.2021.101195
106. Surjana D Halliday GM Damian DL Role of nicotinamide in DNA damage, mutagenesis, and DNA repair J. Nucleic Acids. 2010 25 2010 157591 10.4061/2010/157591
Surjana, D., Halliday, G. M. & Damian, D. L. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J. Nucleic Acids. 25(2010), 157591. 10.4061/2010/157591 (2010).10.4061/2010/157591
107. Frühbeck G Méndez-Giménez L Fernández-Formoso JA Fernández S Rodríguez A Regulation of adipocyte lipolysis Nutr. Res. Rev. 2014 27 1 63 93 10.1017/S095442241400002X 24872083
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J. A., Fernández, S. & Rodríguez, A. Regulation of adipocyte lipolysis. Nutr. Res. Rev. 27(1), 63–93. 10.1017/S095442241400002X (2014) (Epub 2014 May 28 PMID: 24872083).24872083 10.1017/S095442241400002X
108. Bánhegyi G Loewus FA Asard H May JM Smirnoff N Ascorbic acid catabolism: Breakdown pathways in animals and plants Vitamin C, Function and Biochemistry in Animals and Plants 2004 New York Taylor & Francis 35
Bánhegyi, G. & Loewus, F. A. Ascorbic acid catabolism: Breakdown pathways in animals and plants. In Vitamin C, Function and Biochemistry in Animals and Plants (eds Asard, H. et al.) 35 (Taylor & Francis, New York, 2004).
109. Hishikawa D Hashidate T Shimizu T Shindou H Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells J. Lipid Res. 2014 55 5 799 807 10.1194/jlr.R046094 24646950
Hishikawa, D., Hashidate, T., Shimizu, T. & Shindou, H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J. Lipid Res. 55(5), 799–807. 10.1194/jlr.R046094 (2014).24646950 10.1194/jlr.R046094
110. Sivaprakasam S Prasad PD Singh N Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis Pharmacol. Ther. 2016 164 144 151 10.1016/j.pharmthera.2016.04.007 27113407
Sivaprakasam, S., Prasad, P. D. & Singh, N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol. Ther. 164, 144–151. 10.1016/j.pharmthera.2016.04.007 (2016).27113407 10.1016/j.pharmthera.2016.04.007
111. Hooper L Martin N Jimoh OF Kirk C Foster E Abdelhamid AS Reduction in saturated fat intake for cardiovascular disease Cochrane Database Syst. Rev. 2020 5 5 CD011737 10.1002/14651858.CD011737.pub2 32428300
Hooper, L. et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst. Rev. 5(5), CD011737. 10.1002/14651858.CD011737.pub2 (2020).32428300 10.1002/14651858.CD011737.pub2
112. Siri-Tarino PW Sun Q Hu FB Krauss RM Saturated fat, carbohydrate, and cardiovascular disease Am. J. Clin. Nutr. 2010 91 3 502 509 10.3945/ajcn.2008.26285 20089734
Siri-Tarino, P. W., Sun, Q., Hu, F. B. & Krauss, R. M. Saturated fat, carbohydrate, and cardiovascular disease. Am. J. Clin. Nutr. 91(3), 502–509. 10.3945/ajcn.2008.26285 (2010).20089734 10.3945/ajcn.2008.26285
113. Bolsoni-Lopes A Festuccia WT Chimin P Farias TS Torres-Leal FL Cruz MM Andrade PB Hirabara SM Lima FB Alonso-Vale MI Palmitoleic acid (n-7) increases white adipocytes GLUT4 content and glucose uptake in association with AMPK activation Lipids Health Dis. 2014 20 13 199 10.1186/1476-511X-13-199
Bolsoni-Lopes, A. et al. Palmitoleic acid (n-7) increases white adipocytes GLUT4 content and glucose uptake in association with AMPK activation. Lipids Health Dis. 20(13), 199. 10.1186/1476-511X-13-199 (2014).10.1186/1476-511X-13-199
114. Cruz MM Lopes AB Crisma AR de Sá RCC Kuwabara WMT Curi R de Andrade PBM Alonso-Vale MIC Palmitoleic acid (16:1n7) increases oxygen consumption, fatty acid oxidation and ATP content in white adipocytes Lipids Health Dis. 2018 17 1 55 10.1186/s12944-018-0710-z 29554895
Cruz, M. M. et al. Palmitoleic acid (16:1n7) increases oxygen consumption, fatty acid oxidation and ATP content in white adipocytes. Lipids Health Dis. 17(1), 55. 10.1186/s12944-018-0710-z (2018).29554895 10.1186/s12944-018-0710-z
115. Alves SP Marcelino C Portugal PV Bessa RJ Short communication: The nature of heptadecenoic acid in ruminant fats J. Dairy Sci. 2006 89 1 170 173 10.3168/jds.S0022-0302(06)72081-1 16357280
Alves, S. P., Marcelino, C., Portugal, P. V. & Bessa, R. J. Short communication: The nature of heptadecenoic acid in ruminant fats. J. Dairy Sci. 89(1), 170–173. 10.3168/jds.S0022-0302(06)72081-1 (2006) (PMID: 16357280).16357280 10.3168/jds.S0022-0302(06)72081-1
116. Amigo JM Skov T Bro R Coello J Maspoch S Solving GC-MS problems with PARAFAC2 TrAC Trends Anal. Chem. 2008 27 714 725 10.1016/j.trac.2008.05.011
Amigo, J. M., Skov, T., Bro, R., Coello, J. & Maspoch, S. Solving GC-MS problems with PARAFAC2. TrAC Trends Anal. Chem. 27, 714–725. 10.1016/j.trac.2008.05.011 (2008).10.1016/j.trac.2008.05.011
117. Giebelhaus RT Sorochan Armstrong MD de la Mata AP Harynuk JJ Untargeted region of interest selection for gas chromatography–mass spectrometry data using a pseudo F-ratio moving window J. Chromatogr. A 2022 1682 463499 10.1016/j.chroma.2022.463499 36126562
Giebelhaus, R. T., Sorochan Armstrong, M. D., de la Mata, A. P. & Harynuk, J. J. Untargeted region of interest selection for gas chromatography–mass spectrometry data using a pseudo F-ratio moving window. J. Chromatogr. A 1682, 463499. 10.1016/j.chroma.2022.463499 (2022).36126562 10.1016/j.chroma.2022.463499
118. Giebelhaus RT Erland LAE Murch SJ HormonomicsDB: A novel workflow for the untargeted analysis of plant growth regulators and hormones F1000Research 2022 11 119 10.12688/f1000research.124194.1 35529279
Giebelhaus, R. T., Erland, L. A. E. & Murch, S. J. HormonomicsDB: A novel workflow for the untargeted analysis of plant growth regulators and hormones. F1000Research 11, 119 (2022).35529279 10.12688/f1000research.124194.1
119. Monnerie S Comte B Ziegler D Morais JA Pujos-Guillot E Gaudreau P Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: A systematic review Sci. Rep. 2020 10 1 669 10.1038/s41598-019-56909-7 31959772
Monnerie, S. et al. Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: A systematic review. Sci. Rep. 10(1), 669. 10.1038/s41598-019-56909-7 (2020).31959772 10.1038/s41598-019-56909-7
120. Kadowaki T Maegawa H Watada H Yabe D Node K Murohara T Wada J Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan Diabetes Obes. Metab. 2022 24 12 2283 2296 10.1111/dom.14829 35929483
Kadowaki, T. et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes Obes. Metab. 24(12), 2283–2296. 10.1111/dom.14829 (2022).35929483 10.1111/dom.14829
121. National Heart, Lung, and Blood Institute (NHLBI). What is metabolic syndrome? https://www.nhlbi.nih.gov/health/metabolic-syndrome#:~:text=Metabolic%20syndrome%20is%20a%20group,also%20called%20insulin%20resistance%20syndrome. Last 18 May 2022.
122. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
123. Rubio CP Martinez-Subiela S Hernández-Ruiz J Tvarijonaviciute A Ceron JJ Analytical validation of an automated assay for ferric-reducing ability of plasma in dog serum J. Vet. Diagn. Invest. 2017 29 4 574 578 10.1177/1040638717693883 28424022
Rubio, C. P., Martinez-Subiela, S., Hernández-Ruiz, J., Tvarijonaviciute, A. & Ceron, J. J. Analytical validation of an automated assay for ferric-reducing ability of plasma in dog serum. J. Vet. Diagn. Invest. 29(4), 574–578. 10.1177/1040638717693883 (2017).28424022 10.1177/1040638717693883
124. Johnson, M. C. Hyperlipidemia disorders in dogs. Compend. Contin. Educat. Pract. Vet. 27, 361–364 (2005).
125. Littman, M. P. Spontaneous systemic hypertension in 24 cats. J. Vet. Intern. Med. 8(2), 79–86. 10.1111/j.1939-1676.1994.tb03202.x (1994). PMID: 8046680.
126. Jocelyn, P. C. Spectrophotometric assay of thiols. Methods Enzymol. 143, 44–67. 10.1016/0076-6879(87)43013-9 (1987). PMID: 3657559.
